|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Verteporfin
Description of
Verteporfin:
Verteporfin (trade name Visudyne) is a
benzoporphyrin derivative and is a medication used as a photosensitizer
for photodynamic therapy to eliminate the abnormal blood vessels in the
eye associated with conditions such as the wet form of macular
degeneration. Verteporfin accumulates in these abnormal blood vessels
and, when stimulated by nonthermal red light with a wavelength of 693 nm
in the presence of oxygen, produces highly reactive short-lived singlet
oxygen and other reactive oxygen radicals, resulting in local damage to
the endothelium and blockage of the vessels. Verteporfin is also used
off-label for the treatment of central serous retinopathy.
|
MedKoo Code#:
203120
|
|
Name:
Verteporfin
|
|
CAS#:
129497-78-5
Synonym:
Visudyne。DB00460；CL
318,952；Benzoporphyrin
D；Bpd-MA；AIDS350621；AIDS-350621；Benzoporphyrin
derivative monoacid ring A.
IUPAC/Chemical name:
(1): 3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic
acid.
(2): 9-methyl (I) and 13-methyl (II) trans-(±
)-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,
25H-benzo[b]porphine-9,13-dipropanoate .
|
|
Chemical structure: |
Theoretical analysis
: |
|
A
mixture of isomers
|
MedKoo Code#: 203120
Name: Verteporfin
CAS#: 129497-78-5
Chemical Formula: C41H42N4O8
Exact Mass: 718.30026
Molecular Weight: 718.79
Elemental Analysis: C, 68.51; H, 5.89; N, 7.79; O, 17.81
|
|
Availability and price:
This agent is
available
through custom
snythesis
To inquire the quotation and lead time of custom synthesis for this agent,
please send email to
sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control data:
Product will be shipped with supporting
analytical data.
|
|
Information about this agent
|
Verteporfin is A
synthetic light-activated agent with photodynamic activity. Upon
systemic administration, verteporfin accumulates in neovessels in the
eye and, once stimulated by nonthermal red light in the presence of
oxygen, produces highly reactive short-lived singlet oxygen and other
reactive oxygen radicals, resulting in local damage to neovascular
endothelium and blood vessel occlusion. (From
NCI's webpages).
DRUG DESCRIPTION
VISUDYNE® (verteporfin for injection) is a light
activated drug used in photodynamic therapy. The finished drug product
is a lyophilized dark green cake. Verteporfin is a 1:1 mixture of two
regioisomers (I and II)
The chemical names for the verteporfin regioisomers
are: 9-methyl (I) and 13-methyl (II) trans-(±
)-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,
25H-benzo[b]porphine-9,13-dipropanoate. The molecular formula is
C41H42N4O8 with a molecular weight of approximately 718.8. Each mL of
reconstituted VISUDYNE contains:
ACTIVE: Verteporfin, 2 mg. INACTIVES: Lactose, egg phosphatidylglycerol,
dimyristoyl phosphatidylcholine, ascorbyl palmitate and butylated
hydroxytoluene
INDICATIONS
VISUDYNE (verteporfin for injection) therapy is
indicated for the treatment of patients with predominantly classic
subfoveal choroidal neovascularization due to age-related macular
degeneration, pathologic myopia or presumed ocular histoplasmosis. There
is insufficient evidence to indicate VISUDYNE for the treatment of
predominantly occult subfoveal choroidal neovascularization.
Mechanism of Action
VISUDYNE (verteporfin for injection) therapy is a
two-stage process requiring administration of both verteporfin for
injection and nonthermal red light. Verteporfin is transported in the
plasma primarily by lipoproteins. Once verteporfin is activated by light
in the presence of oxygen, highly reactive, short-lived singlet oxygen
and reactive oxygen radicals are generated. Light activation of
verteporfin results in local damage to neovascular endothelium,
resulting in vessel occlusion. Damaged endothelium is known to release
procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene)
and cyclo-oxygenase (eicosanoids such as thromboxane) pathways,
resulting in platelet aggregation, fibrin clot formation and
vasoconstriction. Verteporfin appears to somewhat preferentially
accumulate in neovasculature, including choroidal neovasculature.
However, animal models indicate that the drug is also present in the
retina. Therefore, there may be collateral damage to retinal structures
following photoactivation including the retinal pigmented epithelium and
outer nuclear layer of the retina. The temporary occlusion of choroidal
neovascularization (CNV) following Visudyne therapy has been confirmed
in humans by fluorescein angiography.
Current developer:
QLT Inc。
1: Tekrony AD, Kelly NM, Alexander Fage B,
Cramb DT. Photobleaching Kinetics of Verteporfin and Lemuteporfin in
Cells and Optically Trapped Multilamellar Vesicles Using Two-Photon
Excitation. Photochem Photobiol. 2011 Apr 12. doi:
10.1111/j.1751-1097.2011.00933.x. [Epub ahead of print] PubMed PMID:
21488879.
2: Arevalo JF, Espinoza JV. Single-session combined photodynamic therapy
with verteporfin and intravitreal anti-vascular endothelial growth
factor therapy for chronic central serous chorioretinopathy: a pilot
study at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. 2011 Mar
30. [Epub ahead of print] PubMed PMID: 21448811.
3: Lee YH, Lee EK, Shin KS, Lee KM, Kim JY. INTRAVITREAL RANIBIZUMAB
COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR TREATING POLYPOIDAL
CHOROIDAL VASCULOPATHY. Retina. 2011 Mar 3. [Epub ahead of print] PubMed
PMID: 21386762.
4: Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, Lai TY. IMPROVEMENT IN
MULTIFOCAL ELECTRORETINOGRAPHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC
THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY: A Randomized
Placebo-Controlled Trial. Retina. 2011 Mar 3. [Epub ahead of print]
PubMed PMID: 21386761.
5: Kovacs KD, Quirk MT, Kinoshita T, Gautam S, Ceron OM, Murtha TJ,
Arroyo JG. A retrospective analysis of triple combination therapy with
intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide,
and low-fluence verteporfin photodynamic therapy in patients with
neovascular age-related macular degeneration. Retina. 2011
Mar;31(3):446-52. PubMed PMID: 21336068.
6: Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and
choroidal thickness after verteporfin photodynamic therapy for
polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011
Apr;151(4):594-603.e1. Epub 2011 Feb 4. PubMed PMID: 21295766.
7: Al-Abdullah AA, Al-Assiri A. Resolution of bilateral corneal
neovascularization and lipid keratopathy after photodynamic therapy with
verteporfin. Optometry. 2011 Apr;82(4):212-4. Epub 2011 Jan 8. PubMed
PMID: 21216676.
8: Pece A, Milani P, Isola V, Pierro L. A long-term study of
photodynamic therapy with verteporfin for choroidal neovascularization
at the edge of chorioretinal atrophy in pathologic myopia.
Ophthalmologica. 2011;225(3):161-8. Epub 2011 Jan 5. PubMed PMID:
21212705.
9: Donohue E, Tovey A, Vogl AW, Arns S, Sternberg E, Young RN, Roberge
M. Inhibition of autophagosome formation by the benzoporphyrin
derivative verteporfin. J Biol Chem. 2011 Mar 4;286(9):7290-300. Epub
2010 Dec 30. PubMed PMID: 21193398; PubMed Central PMCID: PMC3044985.
10: Parmeggiani F, Gemmati D, Costagliola C. Thrombophilia in the
occurrence of retinal vascular infarction after photodynamic therapy
with verteporfin using the standard protocol. Arch Ophthalmol. 2010
Dec;128(12):1632; author reply 1632-3. PubMed PMID: 21149800.
11: Bashshur ZF, Schakal AR, El-Mollayess GM, Arafat S, Jaafar D, Salti
HI. RANIBIZUMAB MONOTHERAPY VERSUS SINGLE-SESSION VERTEPORFIN
PHOTODYNAMIC THERAPY COMBINED WITH AS-NEEDED RANIBIZUMAB TREATMENT FOR
THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina.
2010 Nov 30. [Epub ahead of print] PubMed PMID: 21124254.
12: Keane PA, Aghaian E, Ouyang Y, Chong LP, Sadda SR. Acute severe
visual decrease after photodynamic therapy with verteporfin:
spectral-domain OCT features. Ophthalmic Surg Lasers Imaging. 2010
Nov-Dec;41 Suppl:S85-8. doi: 10.3928/15428877-20101031-10. PubMed PMID:
21117609.
13: Bloch SB, Bedda A, Abdel Hadi AM, Larsen M. Contraction of occult
choroidal neovascular membrane and rupture of the retinal pigment
following verteporfin and bevacizumab treatment. Acta Ophthalmol. 2010
Nov 23. doi: 10.1111/j.1755-3768.2010.02023.x. [Epub ahead of print]
PubMed PMID: 21091938.
14: Chan RP, Lai TY. Photodynamic therapy with verteporfin for
vasoproliferative tumour of the retina. Acta Ophthalmol. 2010
Sep;88(6):711-2. PubMed PMID: 21089226.
15: Lazzeri S, Figus M, Di Bartolo E, Rizzo S, Nardi M. Verteporfin
photodynamic therapy for retinal hemangioblastoma associated with Von
Hippel-Lindau disease in a 9-year-old child. Clin Experiment Ophthalmol.
2011 Mar;39(2):179-81. doi: 10.1111/j.1442-9071.2010.02428.x. PubMed
PMID: 21040313.
16: Chen E, Brown DM, Wong TP, Benz MS, Kegley E, Cox J, Fish RH, Kim
RY. Lucentis using Visudyne study: determining the threshold-dose
fluence of verteporfin photodynamic therapy combined with intravitreal
ranibizumab for exudative macular degeneration. Clin Ophthalmol. 2010
Oct 5;4:1073-9. PubMed PMID: 20957143; PubMed Central PMCID: PMC2952607.
17: Sachdeva R, Dadgostar H, Kaiser PK, Sears JE, Singh AD. Verteporfin
photodynamic therapy of six eyes with retinal capillary haemangioma.
Acta Ophthalmol. 2010 Dec;88(8):e334-40. doi:
10.1111/j.1755-3768.2010.02008.x. Epub 2010 Oct 14. PubMed PMID:
20946329.
18: Apte RS, Alexander SL, Henry EC, Wong P, Tuomi L. An observational
retrospective subgroup analysis of verteporfin photodynamic
therapy-naive and previously treated patients in the focus trial.
Retina. 2011 Jan;31(1):56-64. PubMed PMID: 20890244.
19: Fujita K, Yuzawa M, Mori R. RETINAL SENSITIVITY AFTER PHOTODYNAMIC
THERAPY WITH HALF-DOSE VERTEPORFIN FOR CHRONIC CENTRAL SEROUS
CHORIORETINOPATHY: Short-Term Results. Retina. 2010 Sep 30. [Epub ahead
of print] PubMed PMID: 20890236.
20: You IC, Im SK, Lee SH, Yoon KC. Photodynamic therapy with
verteporfin combined with subconjunctival injection of bevacizumab for
corneal neovascularization. Cornea. 2011 Jan;30(1):30-3. PubMed PMID:
20861729.
21: Forte R, Bonavolontŕ P, Benayoun Y, Adenis JP, Robert PY.
Intravitreal ranibizumab and bevacizumab in combination with
full-fluence verteporfin therapy and dexamethasone for exudative
age-related macular degeneration. Ophthalmic Res. 2011;45(3):129-34.
Epub 2010 Sep 17. PubMed PMID: 20847575.
22: Leal S, Silva R, Figueira J, Cachulo ML, Pires I, de Abreu JR,
Cunha-Vaz JG. Photodynamic therapy with verteporfin in polypoidal
choroidal vasculopathy: results after 3 years of follow-up. Retina. 2010
Sep;30(8):1197-205. PubMed PMID: 20827139.
23: Pece A, Russo G, Ricci F, Isola V, Introini U, Querques G.
Verteporfin photodynamic therapy combined with intravitreal
triamcinolone for choroidal neovascularization due to angioid streaks.
Clin Ophthalmol. 2010 Jun 24;4:525-30. PubMed PMID: 20596507; PubMed
Central PMCID: PMC2893762.
24: Koytak A, Erol K, Coskun E, Asik N, Öztürk H, Özertürk Y.
Fluorescein angiography-guided photodynamic therapy with half-dose
verteporfin for chronic central serous chorioretinopathy. Retina. 2010
Nov-Dec;30(10):1698-703. PubMed PMID: 20539254.
25: Hu Z, Rao B, Chen S, Duanmu J. Targeting tissue factor on tumour
cells and angiogenic vascular endothelial cells by factor VII-targeted
verteporfin photodynamic therapy for breast cancer in vitro and in vivo
in mice. BMC Cancer. 2010 May 26;10:235. PubMed PMID: 20504328; PubMed
Central PMCID: PMC2882923.
26: Blasi MA, Tiberti AC, Scupola A, Balestrazzi A, Colangelo E, Valente
P, Balestrazzi E. Photodynamic therapy with verteporfin for symptomatic
circumscribed choroidal hemangioma: five-year outcomes. Ophthalmology.
2010 Aug;117(8):1630-7. Epub 2010 Apr 24. PubMed PMID: 20417564.
27: Rudnisky CJ, Liu C, Ng M, Weis E, Tennant MT. Intravitreal
bevacizumab alone versus combined verteporfin photodynamic therapy and
intravitreal bevacizumab for choroidal neovascularization in age-related
macular degeneration: visual acuity after 1 year of follow-up. Retina.
2010 Apr;30(4):548-54. PubMed PMID: 20386095.
28: Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy
with verteporfin and intravitreal bevacizumab for polypoidal choroidal
vasculopathy. Am J Ophthalmol. 2010 Jun;149(6):947-954.e1. Epub 2010 Mar
26. PubMed PMID: 20346441.
29: Hall RC, Barrett GD, Barry CJ, Constable IJ. Photodynamic Therapy
with Verteporfin for Corneal Neovascularisation. Ophthalmic Surg Lasers
Imaging. 2010 Mar 9:1-3. doi: 10.3928/15428877-20100215-81. [Epub ahead
of print] PubMed PMID: 20337292.
30: Yoon KC, Im SK, Park HY. Recurrent herpes simplex keratitis after
verteporfin photodynamic therapy for corneal neovascularization. Cornea.
2010 Apr;29(4):465-7. PubMed PMID: 20164757.
31: Chan WM, Lim TH, Pece A, Silva R, Yoshimura N. Verteporfin PDT for
non-standard indications--a review of current literature. Graefes Arch
Clin Exp Ophthalmol. 2010 May;248(5):613-26. Epub 2010 Feb 17. Review.
PubMed PMID: 20162298.
32: Nelson M. Re: Verteporfin combination regimens in the treatment of
neovascular age-related macular degeneration. Retina. 2010
Feb;30(2):380; author reply 380-1. PubMed PMID: 20142719.
33: Koizumi H, Hatanaka H. Severe retinal vascular infarction after
photodynamic therapy with verteporfin using the standard protocol. Arch
Ophthalmol. 2010 Feb;128(2):259-62. PubMed PMID: 20142558.
34: Kaiser PK. Combination therapy with verteporfin and anti-VEGF agents
in neovascular age-related macular degeneration: where do we stand? Br J
Ophthalmol. 2010 Feb;94(2):143-5. PubMed PMID: 20139287.
35: Ehmann D, García R. Triple therapy for neovascular age-related
macular degeneration (verteporfin photodynamic therapy, intravitreal
dexamethasone, and intravitreal bevacizumab). Can J Ophthalmol. 2010
Feb;45(1):36-40. PubMed PMID: 20130708.
36: Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic
therapy with verteporfin for treatment of myopic choroidal
neovascularization. Retina. 2010 Mar;30(3):418-24. PubMed PMID:
20094012.
37: García-Fińana M, Murjaneh S, Mahmood S, Harding SP. Baseline
clinical measures and early response predict success in verteporfin
photodynamic therapy for neovascular age-related macular degeneration.
Eye (Lond). 2010 Jul;24(7):1213-9. Epub 2010 Jan 15. PubMed PMID:
20075972.
38: Bhattacharjee H, Deka H, Deka S, Barman MJ, Mazumdar M, Medhi J.
Verteporfin photodynamic therapy of retinal capillary hemangioblastoma
in von Hippel-Lindau disease. Indian J Ophthalmol. 2010
Jan-Feb;58(1):73-5. PubMed PMID: 20029153; PubMed Central PMCID:
PMC2841381.
39: Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S,
Chakravathy U, Carpenter J, Reeves BC; Verteporfin Photodynamic Therapy
Cohort Study Group. Verteporfin photodynamic therapy cohort study:
report 3: cost effectiveness and lessons for future evaluations.
Ophthalmology. 2009 Dec;116(12):2471-77.e1-2. PubMed PMID: 19948278.
40: Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K,
Carpenter J, Guerriero C, Harding SP; Verteporfin Photodynamic Therapy
Cohort Study Group. Verteporfin photodynamic therapy cohort study:
report 2: clinical measures of vision and health-related quality of
life. Ophthalmology. 2009 Dec;116(12):2463-70. PubMed PMID: 19948277.
41: Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J,
Grieve R, Patton WP, Muldrew KA, Peto T, Chakravarthy U; Verteporfin
Photodynamic Therapy Cohort Study Group. Verteporfin photodynamic
therapy cohort study: report 1: effectiveness and factors influencing
outcomes. Ophthalmology. 2009 Dec;116(12):e1-8. PubMed PMID: 19948275.
42: Charisis SK, Naoumidi II, Ginis HS, Detorakis ET, Tsilimbaris MK.
Contact transcleral ciliary body photodynamic therapy with verteporfin
in pigmented rabbits: effect of repeated treatments. Photochem
Photobiol. 2010 Jan-Feb;86(1):194-9. Epub 2009 Nov 12. PubMed PMID:
19912560.
43: Chiou JF, Wang YH, Jou MJ, Liu TZ, Shiau CY.
Verteporfin-photoinduced apoptosis in HepG2 cells mediated by reactive
oxygen and nitrogen species intermediates. Free Radic Res. 2010
Feb;44(2):155-70. PubMed PMID: 19886752.
44: Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, Wolf S. Effects of
combination therapy with verteporfin photodynamic therapy and
ranibizumab in patients with age-related macular degeneration. Acta
Ophthalmol. 2009 Oct 30. [Epub ahead of print] PubMed PMID: 19878113.
45: Debefve E, Pegaz B, Ballini JP, van den Bergh H. Combination therapy
using verteporfin and ranibizumab; optimizing the timing in the CAM
model. Photochem Photobiol. 2009 Nov-Dec;85(6):1400-8. PubMed PMID:
19706144.
46: Kim KS, Lee WK. Photodynamic therapy with verteporfin for avascular
serous pigment epithelial detachment in elderly Koreans. Retina. 2010
Jan;30(1):93-9. PubMed PMID: 19696702.
47: Ahn JK, Moon HJ. Changes in aqueous vascular endothelial growth
factor and pigment epithelium-derived factor after ranibizumab alone or
combined with verteporfin for exudative age-related macular
degeneration. Am J Ophthalmol. 2009 Nov;148(5):718-724.e1. Epub 2009 Aug
11. PubMed PMID: 19674731.
48: Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, Li XX. Photodynamic
therapy for acute central serous chorioretinopathy: the safe effective
lowest dose of verteporfin. Retina. 2009 Sep;29(8):1155-61. PubMed PMID:
19629018.
49: Awan MA, Chavan R, Peh KK, Yang YC. The effect of the first
application of verteporfin photodynamic therapy on lesion growth in
choroidal neovascularisation and its potential impact on combination
therapy. Clin Exp Optom. 2009 Sep;92(5):440-3. Epub 2009 Jun 22. PubMed
PMID: 19552669.
50: Verteporfin: restriction of indications: labelling change. A welcome
move. A negative risk-benefit balance in neovascular forms of ARMD with
"occult" lesions. Prescrire Int. 2008 Oct;17(97):192. PubMed PMID:
19536923.
51: Kaiser PK; Visudyne In Occult CNV (VIO) study group. Verteporfin PDT
for subfoveal occult CNV in AMD: two-year results of a randomized trial.
Curr Med Res Opin. 2009 Aug;25(8):1853-60. PubMed PMID: 19530976.
52: Han DP, McAllister JT, Weinberg DV, Kim JE, Wirostko WJ. Combined
intravitreal anti-VEGF and verteporfin photodynamic therapy for
juxtafoveal and extrafoveal choroidal neovascularization as an
alternative to laser photocoagulation. Eye (Lond). 2010 Apr;24(4):713-6.
Epub 2009 Jun 5. PubMed PMID: 19498454.
53: Rodrigues M, Meira D, Batista S, Carrilho MM. Accidental pregnancy
exposure to verteporfin: obstetrical and neonatal outcomes: a case
report. Aust N Z J Obstet Gynaecol. 2009 Apr;49(2):236-7. PubMed PMID:
19432621.
54: Lu F, Hu Z, Sinard J, Garen A, Adelman RA. Factor VII-verteporfin
for targeted photodynamic therapy in a rat model of choroidal
neovascularization. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3890-6.
Epub 2009 Apr 8. PubMed PMID: 19357351.
55: Akens MK, Hardisty MR, Wilson BC, Schwock J, Whyne CM, Burch S, Yee
AJ. Defining the therapeutic window of vertebral photodynamic therapy in
a murine pre-clinical model of breast cancer metastasis using the
photosensitizer BPD-MA (Verteporfin). Breast Cancer Res Treat. 2010
Jan;119(2):325-33. Epub 2009 Mar 5. PubMed PMID: 19263216.
56: Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee, Boyer
DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter
JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA. Verteporfin
photodynamic therapy combined with intravitreal bevacizumab for
neovascular age-related macular degeneration. Ophthalmology. 2009
Apr;116(4):747-55, 755.e1. Epub 2009 Feb 25. PubMed PMID: 19243834.
57: Türkçüoğlu P, Ilhan N, Kurt J, Aydemir O, Celiker U. The protective
role of Visudyne eyeglass against VEGF synthesis after photodynamic
therapy with verteporfin. Acta Ophthalmol. 2009 Nov;87(8):871-4. Epub .
PubMed PMID: 19220205.
58: Lüke M, Ziemssen F, Völker M, Altpeter E, Beutel J, Besch D,
Bartz-Schmidt KU, Gelisken F. Full macular translocation (FMT) versus
photodynamic therapy (PDT) with verteporfin in the treatment of
neovascular age-related macular degeneration: 2-year results of a
prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch
Clin Exp Ophthalmol. 2009 Jun;247(6):745-54. Epub 2009 Feb 12. PubMed
PMID: 19214552.
59: Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the
treatment of neovascular age-related macular degeneration. Retina. 2009
Feb;29(2):133-48. Review. PubMed PMID: 19202423.
60: Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR
Study Group. Ranibizumab versus verteporfin photodynamic therapy for
neovascular age-related macular degeneration: Two-year results of the
ANCHOR study. Ophthalmology. 2009 Jan;116(1):57-65.e5. PubMed PMID:
19118696.
61: Murjaneh S, García-Fińana M, Mahmood S, Lenfestey PM, Taylor SA,
Pearce IA, Briggs MC, Heimann H, Harding SP. Observational prospective
study of the effectiveness in routine clinical practice of verteporfin
photodynamic therapy in patients with neovascular age-related macular
degeneration. Br J Ophthalmol. 2009 Apr;93(4):468-73. Epub 2008 Dec 15.
PubMed PMID: 19074914.
62: Chan RP, Lai TY. Photodynamic therapy with verteporfin for
vasoproliferative tumour of the retina. Acta Ophthalmol. 2008 Dec 2.
[Epub ahead of print] PubMed PMID: 19053958.
63: Kiss CG, Simader C, Michels S, Schmidt-Erfurth U. Combination of
verteporfin photodynamic therapy and ranibizumab: effects on retinal
anatomy, choroidal perfusion and visual function in the protect study.
Br J Ophthalmol. 2008 Dec;92(12):1620-7. PubMed PMID: 19029163.
64: Lie S, Aue A, Sacu S, Simader C, Polak K, Schmidt-Erfurth U.
Time-course and characteristic morphology of retinal changes following
combination of verteporfin therapy and intravitreal triamcinolone in
neovascular age-related macular degeneration. Acta Ophthalmol. 2010
Mar;88(2):212-7. Epub 2008 Nov 11. PubMed PMID: 19016662.
65: Costagliola C, Campa C, Incorvaia C, Parmeggiani F, Menzione M,
Della Corte M, Rinaldi M, Romano M, Semeraro F. Verteporfin photodynamic
therapy for subfoveal choroidal neovascularization in pathologic myopia:
a 12-month retrospective review. Eur J Ophthalmol. 2008
Nov-Dec;18(6):955-9. Erratum in: Eur J Ophthalmol. 2009
Mar-Apr;19(2):329. PubMed PMID: 18988168.
66: Hussain N, Khanna R, Das T, Narayanan R, Sunday OT, Bansal AG, Reddy
R. Two years follow-up outcome of verteporfin therapy for subfoveal
choroidal neovascularization in pathologic myopia in Indian eyes. Indian
J Ophthalmol. 2008 Nov-Dec;56(6):465-8. PubMed PMID: 18974516; PubMed
Central PMCID: PMC2612981.
67: Theelen T, Hoyng CB. Intravenous diclofenac as prophylactic
treatment for verteporfin-associated low back pain. Eur J Ophthalmol.
2008 Sep-Oct;18(5):805-8. PubMed PMID: 18850562.
68: Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin
for age-related macular degeneration or polypoidal choroidal
vasculopathy: comparison of the presence of serous retinal pigment
epithelial detachment. Br J Ophthalmol. 2008 Dec;92(12):1642-7. Epub
2008 Sep 9. PubMed PMID: 18782798.
69: Schmidt-Erfurth U, Wolf S; PROTECT Study Group. Same-day
administration of verteporfin and ranibizumab 0.5 mg in patients with
choroidal neovascularisation due to age-related macular degeneration. Br
J Ophthalmol. 2008 Dec;92(12):1628-35. Epub 2008 Sep 4. PubMed PMID:
18772178.
70: Eskelin S, Tommila P, Palosaari T, Kivelä T. Photodynamic therapy
with verteporfin to induce regression of aggressive retinal
astrocytomas. Acta Ophthalmol. 2008 Nov;86(7):794-9. Epub 2008 Aug 27.
PubMed PMID: 18759802.
71: Lee MW, Yeo I, Wong D, Ang CL. Photodynamic therapy with verteporfin
for polypoidal choroidal vasculopathy. Eye (Lond). 2009
Jun;23(6):1417-22. Epub 2008 Aug 29. PubMed PMID: 18756283.
72: Windisch R, Kozousek V. Intravitreal bevacizumab compared with
photodynamic therapy with verteporfin for group 2a parafoveal retinal
telangiectasis. Can J Ophthalmol. 2008 Aug;43(4):489-90. PubMed PMID:
18711474.
73: Japanese Age-Related Macular Degeneration Trial (JAT) Study Group.
Photodynamic therapy with verteporfin in Japanese patients with
subfoveal choroidal neovascularization secondary to age-related macular
degeneration (AMD): results of the Japanese AMD Trial (JAT) extension.
Jpn J Ophthalmol. 2008 Mar-Apr;52(2):99-107. Epub 2008 Apr 30. PubMed
PMID: 18626732.
74: Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfin and
bevacizumab therapy for choroidal neovascularization secondary to
punctate inner choroidopathy during pregnancy. Eye (Lond). 2009
Jun;23(6):1479. Epub 2008 Jul 11. PubMed PMID: 18617903.
75: Park S, Hong SP, Oh TY, Bang S, Chung JB, Song SY. Paclitaxel
augments cytotoxic effect of photodynamic therapy using verteporfin in
gastric and bile duct cancer cells. Photochem Photobiol Sci. 2008
Jul;7(7):769-74. Epub 2008 May 15. PubMed PMID: 18597023.
76: Soubrane G, Harding SP, Wolf S, Weichselberger A. Verteporfin
therapy in occult with no classic CNV due to AMD: results of the
Photodynamic Therapy in Occult-Only Lesions study. Eye (Lond). 2009
Apr;23(4):791-800. Epub 2008 Jun 27. PubMed PMID: 18583995.
77: Stephan H, Boeloeni R, Eggert A, Bornfeld N, Schueler A.
Photodynamic therapy in retinoblastoma: effects of verteporfin on
retinoblastoma cell lines. Invest Ophthalmol Vis Sci. 2008
Jul;49(7):3158-63. PubMed PMID: 18579764.
78: Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy
with verteporfin in age-related macular degeneration: a systematic
review of efficacy, safety, treatment modifications and pharmacoeconomic
properties. Acta Ophthalmol. 2009 Mar;87(2):118-32. Epub 2008 Jun 13.
Review. PubMed PMID: 18577193.
79: Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin
photodynamic therapy for acute central serous chorioretinopathy:
one-year results of a randomized controlled trial. Ophthalmology. 2008
Oct;115(10):1756-65. Epub 2008 Jun 5. PubMed PMID: 18538401.
80: Chen B, Crane C, He C, Gondek D, Agharkar P, Savellano MD, Hoopes
PJ, Pogue BW. Disparity between prostate tumor interior versus
peripheral vasculature in response to verteporfin-mediated
vascular-targeting therapy. Int J Cancer. 2008 Aug 1;123(3):695-701.
PubMed PMID: 18498134.
81: Ranchod TM, Guercio JR, Ying GS, Brucker AJ, Stoltz RA. Effect of
aspirin therapy on photodynamic therapy with verteporfin for choroidal
neovascularization. Retina. 2008 May;28(5):711-6. PubMed PMID: 18463514.
82: Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA.
Intravitreal injection of bevacizumab combined with verteporfin
photodynamic therapy for choroidal neovascularization in age-related
macular degeneration. Retina. 2008 May;28(5):675-81. PubMed PMID:
18463509.
83: Parodi MB, Iacono P, Ravalico G. Verteporfin photodynamic therapy
for anterior segment neovascularization secondary to ischaemic central
retinal vein occlusion. Clin Experiment Ophthalmol. 2008
Apr;36(3):232-7. PubMed PMID: 18412591.
84: Ryan EH Jr, Kjellbotn R. A masking device and method to create
custom laser exposure patterns for verteporfin photodynamic therapy.
Retina. 2008 Apr;28(4):622-7. PubMed PMID: 18398366.
85: Lipski A, Bornfeld N, Jurklies B. Photodynamic therapy with
verteporfin in paediatric and young adult patients: long-term treatment
results of choroidal neovascularisations. Br J Ophthalmol. 2008
May;92(5):655-60. Epub 2008 Mar 20. PubMed PMID: 18356263.
86: Bernstein ZP, Dougherty T, Gollnick S, Schwartz SA, Mahajan SD,
Kepner J, Sumlin A, Stewart C, Wallace P, Adal A, Walder H, Poiesz B.
Photopheresis in HIV-1 infected patients utilizing benzoporphyrin
derivative (BPD) verteporfin and light. Curr HIV Res. 2008
Mar;6(2):152-63. PubMed PMID: 18336263.
87: Debefve E, Pegaz B, van den Bergh H, Wagničres G, Lange N, Ballini
JP. Video monitoring of neovessel occlusion induced by photodynamic
therapy with verteporfin (Visudyne), in the CAM model. Angiogenesis.
2008;11(3):235-43. Epub 2008 Mar 7. PubMed PMID: 18324477; PubMed
Central PMCID: PMC2494573.
88: Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group.
Ranibizumab combined with verteporfin photodynamic therapy in
neovascular age-related macular degeneration (FOCUS): year 2 results. Am
J Ophthalmol. 2008 May;145(5):862-74. Epub 2008 Mar 5. PubMed PMID:
18321465.
89: Incorvaia C, Campa C, Parmeggiani F, Menzione M, D'Angelo S, Della
Corte M, Rinaldi M, Romano M, Dell'omo R, Costagliola C. 12-month
retrospective study and review of photodynamic therapy with verteporfin
for subfoveal choroidal neovascularization in age-related macular
degeneration. Retina. 2008 Feb;28(2):289-97. PubMed PMID: 18301052.
90: Williams MA, Mulholland C, Silvestri G. Photodynamic therapy for
central serous chorioretinopathy using a reduced dose of verteporfin.
Can J Ophthalmol. 2008 Feb;43(1):123. PubMed PMID: 18219357.
91: Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hara
W, Yoshida T, Tokoro T, Mochizuki M. Photodynamic therapy with
verteporfin for choroidal neovascularization of pathologic myopia in
Japanese patients: comparison with nontreated controls. Am J Ophthalmol.
2008 Mar;145(3):518-526. Epub 2008 Jan 22. PubMed PMID: 18207125.
92: Bernstein PS, Horn RS. Verteporfin photodynamic therapy involving
the optic nerve for peripapillary choroidal neovascularization. Retina.
2008 Jan;28(1):81-4. PubMed PMID: 18185142.
93: Yusuf TE, Matthes K, Brugge WR. EUS-guided photodynamic therapy with
verteporfin for ablation of normal pancreatic tissue: a pilot study in a
porcine model (with video). Gastrointest Endosc. 2008 May;67(6):957-61.
Epub 2008 Feb 21. PubMed PMID: 18178203.
94: Schmidt-Erfurth U, Sacu S; Early Retreatment Study Group. Randomized
multicenter trial of more intense and standard early verteporfin
treatment of neovascular age-related macular degeneration.
Ophthalmology. 2008 Jan;115(1):134-40. PubMed PMID: 18166408.
95: Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide
as adjunctive treatment to verteporfin in neovascular age-related
macular degeneration: a prospective randomized trial. Ophthalmology.
2007 Dec;114(12):2183-9. PubMed PMID: 18054638.
96: Hussain N, Das T, Khanna R, Ram LM, Sumasri K. One-year results of
verteporfin therapy for subretinal neovascularization associated with
type 2A parafoveal telengiectasia. Clin Ophthalmol. 2007 Dec;1(4):483-8.
PubMed PMID: 19668526; PubMed Central PMCID: PMC2704534.
97: Rosenfeld PJ, Boyer DS, Bressler NM, Fish G, Grizzard WS, Hao Y,
Hnik P, Hudson HL, Singerman L, Slakter JS; VALIO Study Group.
Verteporfin therapy of subfoveal occult choroidal neovascularization in
AMD using delayed light application: one-year results of the VALIO
Study. Am J Ophthalmol. 2007 Dec;144(6):970-972. PubMed PMID: 18036873.
98: Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib
compared to photodynamic therapy with verteporfin and to standard care
in the treatment of subfoveal wet age-related macular degeneration in
Canada. Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5. PubMed
PMID: 18035208.
99: Parmeggiani F, Costagliola C, Gemmati D, D'Angelo S, Perri P,
Scapoli GL, Catozzi L, Federici F, Sebastiani A, Incorvaia C. Predictive
role of coagulation-balance gene polymorphisms in the efficacy of
photodynamic therapy with verteporfin for classic choroidal
neovascularization secondary to age-related macular degeneration.
Pharmacogenet Genomics. 2007 Dec;17(12):1039-46. PubMed PMID: 18004208.
100: Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin
BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for
neovascular age-related macular degeneration. Arch Ophthalmol. 2007
Oct;125(10):1357-61. PubMed PMID: 17923543.
101: Lavie G, Barliya T, Mandel M, Blank M, Ron Y, Orenstein A, Livnat
T, Friedman N, Weiner L, Sheves M, Weinberger D. "Competitive
quenching": a mechanism by which perihydroxylated perylenequinone
photosensitizers can prevent adverse phototoxic damage caused by
verteporfin during photodynamic therapy. Photochem Photobiol. 2007
Sep-Oct;83(5):1270-7. PubMed PMID: 17880523.
102: Suh SC, Jin SY, Bae SH, Kim CG, Kim JW. Retinal capillary
hemangioma treated with verteporfin photodynamic therapy and
intravitreal triamcinolone acetonide. Korean J Ophthalmol. 2007
Sep;21(3):178-84. PubMed PMID: 17804927; PubMed Central PMCID:
PMC2629681.
103: Lee JM, Nam WH, Kim HK. Photodynamic therapy with verteporfin for
choroidal neovascularization in patients with angioid streaks. Korean J
Ophthalmol. 2007 Sep;21(3):142-5. PubMed PMID: 17804918; PubMed Central
PMCID: PMC2629678.
104: Yoon KC, You IC, Kang IS, Im SK, Ahn JK, Park YG, Ahn KY.
Photodynamic therapy with verteporfin for corneal neovascularization. Am
J Ophthalmol. 2007 Sep;144(3):390-395. Epub 2007 Jul 16. PubMed PMID:
17631268.
105: Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, Eckardt
C, Bartz-Schmidt KU, Grisanti S. Influence of verteporfin photodynamic
therapy on inflammation in human choroidal neovascular membranes
secondary to age-related macular degeneration. Retina. 2007
Jul-Aug;27(6):713-23. PubMed PMID: 17621180.
106: Adjunctive Diclofenac with Verteporfin (ADD-V) Study Group, Boyer
DS, Beer PM, Joffe L, Koester JM, Marx JL, Weisberger A, Yoser SL.
Effect of adjunctive diclofenac with verteporfin therapy to treat
choroidal neovascularization due to age-related macular degeneration:
phase II study. Retina. 2007 Jul-Aug;27(6):693-700. PubMed PMID:
17621177.
107: Luttrull JK, Spink CJ. Prolongation of choroidal hypofluorescence
following combined verteporfin photodynamic therapy and intravitreal
triamcinolone acetonide injection. Retina. 2007 Jul-Aug;27(6):688-92.
PubMed PMID: 17621176.
108: Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab
combined and alone in choroidal neovascularization due to age-related
macular degeneration. Ophthalmology. 2007 Jun;114(6):1179-85. PubMed
PMID: 17544776.
109: Tatar O, Adam A, Shinoda K, Eckert T, Scharioth GB, Klein M,
Yoeruek E, Bartz-Schmidt KU, Grisanti S. Matrix metalloproteinases in
human choroidal neovascular membranes excised following verteporfin
photodynamic therapy. Br J Ophthalmol. 2007 Sep;91(9):1183-9. Epub 2007
May 2. PubMed PMID: 17475706; PubMed Central PMCID: PMC1954910.
110: Pece A, Isola V, Vadalŕ M, Calori G. Photodynamic therapy with
verteporfin for choroidal neovascularization associated with retinal
pigment epithelial detachment in age-related macular degeneration.
Retina. 2007 Mar;27(3):342-8. PubMed PMID: 17460590.
111: Ayaru L, Wittmann J, Macrobert AJ, Novelli M, Bown SG, Pereira SP.
Photodynamic therapy using verteporfin photosensitization in the
pancreas and surrounding tissues in the Syrian golden hamster.
Pancreatology. 2007;7(1):20-7. Epub 2007 Apr 18. PubMed PMID: 17449962.
112: Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y. Long-term follow-up of
polypoidal choroidal vasculopathy after photodynamic therapy with
verteporfin. Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1569-71.
Epub 2007 Apr 17. PubMed PMID: 17437122.
113: Zhou X, Chen B, Hoopes PJ, Hasan T, Pogue BW. Tumor vascular area
correlates with photosensitizer uptake: analysis of verteporfin
microvascular delivery in the Dunning rat prostate tumor. Photochem
Photobiol. 2006 Sep-Oct;82(5):1348-57. PubMed PMID: 17421078.
114: Park CH, Smith BT, Oh M, Fekrat S. Optical coherence tomography
following photodynamic therapy with verteporfin for subfoveal
predominantly classic choroidal neovascularization. Ann Ophthalmol
(Skokie). 2006 Summer;38(2):121-5. PubMed PMID: 17416941.
115: Ghanchi FD, Fullarton J, Blake J, Harding SP; PDTUG(UK). The
introduction of verteporfin photodynamic therapy in the UK: PDT users
group (PDTUG) surveillance programme report 1. Eye (Lond). 2008
May;22(5):671-7. Epub 2007 Mar 16. PubMed PMID: 17363929.
116: Kaiser PK. Verteporfin photodynamic therapy and anti-angiogenic
drugs: potential for combination therapy in exudative age-related
macular degeneration. Curr Med Res Opin. 2007 Mar;23(3):477-87. Review.
PubMed PMID: 17355729.
117: Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU.
Intravitreal bevacizumab (Avastin) in combination with verteporfin
photodynamic therapy for choroidal neovascularization associated with
age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp
Ophthalmol. 2007 Sep;245(9):1273-80. Epub 2007 Feb 28. PubMed PMID:
17333238.
118: Pece A, Vadalŕ M, Isola V, Matranga D. Photodynamic therapy with
verteporfin for juxtafoveal choroidal neovascularization in pathologic
myopia: a long-term follow-up study. Am J Ophthalmol. 2007
Mar;143(3):449-54. Epub 2006 Dec 22. PubMed PMID: 17317390.
119: Sharp DM, Lai S, Markey CM. Photodynamic therapy with verteporfin
for choroidal neovascularization due to age-related macular degeneration
and other causes: a New Zealand outcomes study. Clin Experiment
Ophthalmol. 2007 Jan-Feb;35(1):24-31. PubMed PMID: 17300567.
120: Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal
neovascularization due to age-related macular degeneration: verteporfin
PDT, bevacizumab, and dexamethasone. Retina. 2007 Feb;27(2):133-40.
PubMed PMID: 17290193.
121: Chaudhry NA, Lavaque AJ, Tom DE, Liggett PE. Large submacular
hemorrhage following PDT with verteporfin in patients with occult CNVM
secondary to age-related macular degeneration. Ophthalmic Surg Lasers
Imaging. 2007 Jan-Feb;38(1):64-8. PubMed PMID: 17278540.
122: Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P,
Grisanti S, Herzau V, Bartz-Schmidt KU. Full macular translocation
versus photodynamic therapy with verteporfin in the treatment of
neovascular age-related macular degeneration: 1-year results of a
prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch
Clin Exp Ophthalmol. 2007 Aug;245(8):1085-95. PubMed PMID: 17219106.
123: Paskowitz DM, Donohue-Rolfe KM, Yang H, Yasumura D, Matthes MT,
Hosseini K, Graybeal CM, Nune G, Zarbin MA, Lavail MM, Duncan JL.
Neurotrophic factors minimize the retinal toxicity of verteporfin
photodynamic therapy. Invest Ophthalmol Vis Sci. 2007 Jan;48(1):430-7.
PubMed PMID: 17197564.
124: Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy and
triamcinolone acetonide: convergent modes of action for treatment of
neovascular age-related macular degeneration. Eur J Ophthalmol. 2006
Nov-Dec;16(6):824-34. Review. PubMed PMID: 17191188.
125: Soucek P, Cihelkova I. Photodynamic therapy with Verteporfin in
subfoveal choroidal metastasis of breast carcinoma (a controlled case).
Neuro Endocrinol Lett. 2006 Dec;27(6):725-8. PubMed PMID: 17187011.
126: Hussain N, Das T, Khanna R, Sumasri K, Mohan Ram LS. Verteporfin
therapy for neovascular age-related macular degeneration in Indian eyes.
Jpn J Ophthalmol. 2006 Nov-Dec;50(6):524-8. Epub 2006 Dec 18. PubMed
PMID: 17180526.
127: Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH Jr, Sternberg P
Jr, Aaberg TM Sr, Aaberg TM Jr, Weisberger A. Verteporfin therapy for
CNV secondary to OHS. Ophthalmology. 2006 Dec;113(12):2371.e1-3. PubMed
PMID: 17157140.
128: Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A.
Combined photodynamic therapy with verteporfin and intravitreal
bevacizumab for choroidal neovascularization in age-related macular
degeneration. Retina. 2006 Nov-Dec;26(9):988-93. PubMed PMID: 17151484.
129: Fackler TK, Reddy S, Bearelly S, Stinnett S, Fekrat S, Cooney MJ.
Retrospective review of eyes with neovascular age-related macular
degeneration treated with photodynamic therapy with verteporfin and
intravitreal triamcinolone. Ann Acad Med Singapore. 2006
Oct;35(10):701-5. PubMed PMID: 17102894.
130: Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC,
Kotlovker D, Chung CY, Kim RY; FOCUS Study Group. Ranibizumab combined
with verteporfin photodynamic therapy in neovascular age-related macular
degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006
Nov;124(11):1532-42. Erratum in: Arch Ophthalmol. 2007 Jan;125(1):138.
PubMed PMID: 17101999.
131: Hussain N, Das T, Rawal H, Kallukuri SB, Mohan Ram LS, Khanna R.
Combination therapy of intravitreal triamcinolone and photodynamic
therapy with verteporfin for subfoveal choroidal neovascularization.
Indian J Ophthalmol. 2006 Dec;54(4):247-50. PubMed PMID: 17090876.
132: Bansback N, Davis S, Brazier J. Using contrast sensitivity to
estimate the cost-effectiveness of verteporfin in patients with
predominantly classic age-related macular degeneration. Eye (Lond). 2007
Dec;21(12):1455-63. Epub 2006 Nov 10. PubMed PMID: 17086167.
133: Aggio FB, Melo GB, Höfling-Lima AL, Eid Farah M. Photodynamic
therapy with verteporfin combined with intravitreal injection of
bevacizumab for exudative age-related macular degeneration. Acta
Ophthalmol Scand. 2006 Dec;84(6):831-3. PubMed PMID: 17083553.
134: Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation
treated with a combination of intravitreal triamcinolone acetonide and
photodynamic therapy with verteporfin. Eur J Ophthalmol. 2006
Sep-Oct;16(5):705-10. PubMed PMID: 17061221.
135: Mauget-Fa˙sse M, Quaranta-El Maftouhi M, De La Marničrre E, Leys A.
Photodynamic therapy with verteporfin in the treatment of exudative
idiopathic polypoidal choroidal vasculopathy. Eur J Ophthalmol. 2006
Sep-Oct;16(5):695-704. PubMed PMID: 17061220.
136: Isola V, Pece A, Pierro L. Photodynamic therapy with verteporfin of
choroidal malignancy from breast cancer. Am J Ophthalmol. 2006
Nov;142(5):885-7. PubMed PMID: 17056382.
137: Fossarello M, Peiretti E. Acute respiratory distress due to
verteporfin infusion for photodynamic therapy. Arch Ophthalmol. 2006
Oct;124(10):1509-10. PubMed PMID: 17030732.
138: Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy
JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for
neovascular age-related macular degeneration. N Engl J Med. 2006 Oct
5;355(14):1432-44. PubMed PMID: 17021319.
139: Park SP, Ko DA, Chung H, Yu HG. Photodynamic therapy with
verteporfin for juxtafoveal choroidal neovascularization in serpiginous
choroiditis. Ophthalmic Surg Lasers Imaging. 2006 Sep-Oct;37(5):425-8.
PubMed PMID: 17017204.
140: Isola V, Pece A, Parodi MB. Choroidal ischemia after photodynamic
therapy with verteporfin for choroidal neovascularization. Am J
Ophthalmol. 2006 Oct;142(4):680-3. PubMed PMID: 17011867.
141: Tatar O, Shinoda K, Adam A, Eckert T, Eckardt C, Lucke K, Deuter C,
Bartz-Schmidt KU, Grisanti S. Effect of verteporfin photodynamic therapy
on endostatin and angiogenesis in human choroidal neovascular membranes.
Br J Ophthalmol. 2007 Feb;91(2):166-73. Epub 2006 Sep 20. PubMed PMID:
16987895; PubMed Central PMCID: PMC1857619.
142: Pece A, Isola V, Vadalŕ M, Matranga D. Photodynamic therapy with
verteporfin for subfoveal choroidal neovascularization secondary to
pathologic myopia: long-term study. Retina. 2006 Sep;26(7):746-51.
PubMed PMID: 16963846.
143: Nowak-Sliwinska P, Karocki A, Elas M, Pawlak A, Stochel G, Urbanska
K. Verteporfin, photofrin II, and merocyanine 540 as PDT
photosensitizers against melanoma cells. Biochem Biophys Res Commun.
2006 Oct 20;349(2):549-55. Epub 2006 Aug 22. PubMed PMID: 16945338.
144: Bylsma GW, Harper CA, Dutton F, Johnson NC, Beaumont P, Guymer RH.
Australian Angiogram Review Panel--monitoring the use of photodynamic
therapy with verteporfin. Clin Experiment Ophthalmol. 2006
Aug;34(6):550-6. PubMed PMID: 16925702.
145: Tsilimbaris MK, Charisis SK, Naoumidi T, Panteleontidis V, Skondra
D, Christodoulakis E, Naoumidi I. Contact transscleral ciliary body
photodynamic therapy in pigmented rabbits using verteporfin and diode
laser: evaluation of treatment parameters. Curr Eye Res. 2006
Jul-Aug;31(7-8):577-85. PubMed PMID: 16877266.
146: Fenton C, Perry CM. Verteporfin: a review of its use in the
management of subfoveal choroidal neovascularisation. Drugs Aging.
2006;23(5):421-45. Review. PubMed PMID: 16823995.
147: Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M,
Bartz-Schmidt KU, Grisanti S. Expression of VEGF and PEDF in choroidal
neovascular membranes following verteporfin photodynamic therapy. Am J
Ophthalmol. 2006 Jul;142(1):95-104. PubMed PMID: 16815256.
148: Ergun E, Maár N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K,
Wedrich A, Stur M. Photodynamic therapy with verteporfin and
intravitreal triamcinolone acetonide in the treatment of neovascular
age-related macular degeneration. Am J Ophthalmol. 2006
Jul;142(1):10-16. PubMed PMID: 16815246.
149: Opitz I, Krueger T, Pan Y, Altermatt HJ, Wagničres G, Ris HB.
Preclinical comparison of mTHPC and verteporfin for intracavitary
photodynamic therapy of malignant pleural mesothelioma. Eur Surg Res.
2006;38(3):333-9. Epub 2006 Jun 19. PubMed PMID: 16785733.
150: Stewart JM. Half dose verteporfin PDT for central serous
chorioretinopathy. Br J Ophthalmol. 2006 Jul;90(7):805-6. PubMed PMID:
16782941; PubMed Central PMCID: PMC1857128.
151: Kozak I, Cheng L, Cochran DE, Freeman WR. Phase I clinical trial
results of verteporfin enhanced feeder vessel therapy in subfoveal
choroidal neovascularisation in age related macular degeneration. Br J
Ophthalmol. 2006 Sep;90(9):1152-6. Epub 2006 Jun 14. PubMed PMID:
16774958; PubMed Central PMCID: PMC1857394.
152: Tatar O, Kaiserling E, Adam A, Gelisken F, Shinoda K, Völker M,
Lafaut BA, Bartz-Schmidt KU, Grisanti S. Consequences of verteporfin
photodynamic therapy on choroidal neovascular membranes. Arch
Ophthalmol. 2006 Jun;124(6):815-23. PubMed PMID: 16769835.
153: Wirthlin R, Song A, Song J, Rosenfeld PJ. Verteporfin photodynamic
therapy of choroidal neovascularization secondary to ocular
toxoplasmosis. Arch Ophthalmol. 2006 May;124(5):741-3. PubMed PMID:
16682600.
154: Pieramici DJ, Bressler SB, Koester JM, Bressler NM. Occult with no
classic subfoveal choroidal neovascular lesions in age-related macular
degeneration: clinically relevant natural history information in larger
lesions with good vision from the Verteporfin in Photodynamic Therapy
(VIP) Trial: VIP Report No. 4. Arch Ophthalmol. 2006 May;124(5):660-4.
PubMed PMID: 16682587.
155: Mori R, Kelkar A, De Laey JJ. Photodynamic therapy with verteporfin
in Belgian patients with subfoveal choroidal neovascularization
secondary to age-related macular degeneration. Bull Soc Belge Ophtalmol.
2006;(299):57-64. PubMed PMID: 16681088.
156: Jurklies B, Bornfeld N, Schilling H. Photodynamic therapy using
verteporfin for choroidal neovascularization associated with angioid
streaks--long-term effects. Ophthalmic Res. 2006;38(4):209-17. Epub 2006
May 4. PubMed PMID: 16679809.
157: Soucek P, Cihelkova I. Photodynamic therapy with verteporfin in
subfoveal amelanotic choroidal melanoma (A controlled case). Neuro
Endocrinol Lett. 2006 Feb-Apr;27(1-2):145-8. PubMed PMID: 16648785.
158: Kramarenko GG, Wilke WW, Dayal D, Buettner GR, Schafer FQ.
Ascorbate enhances the toxicity of the photodynamic action of
Verteporfin in HL-60 cells. Free Radic Biol Med. 2006 May
1;40(9):1615-27. Epub 2006 Jan 19. PubMed PMID: 16632121; PubMed Central
PMCID: PMC2626188.
159: Cilliers H, Harper CA. Photodynamic therapy with Verteporfin for
vascular leakage from a combined hamartoma of the retina and retinal
pigment epithelium. Clin Experiment Ophthalmol. 2006 Mar;34(2):186-8.
PubMed PMID: 16626442.
160: Petermeier K, Tatar O, Inhoffen W, Völker M, Lafaut BA, Henke-Fahle
S, Gelisken F, Ziemssen F, Bopp S, Bartz-Schmidt KU, Grisanti S.
Verteporfin photodynamic therapy induced apoptosis in choroidal
neovascular membranes. Br J Ophthalmol. 2006 Aug;90(8):1034-9. Epub 2006
Apr 13. PubMed PMID: 16613924; PubMed Central PMCID: PMC1857222.
161: Schmidt-Erfurth U, Michels S, Augustin A. Perspectives on
verteporfin therapy combined with intravitreal corticosteroids. Arch
Ophthalmol. 2006 Apr;124(4):561-3. Review. PubMed PMID: 16606885.
162: Mauget-Fa˙sse M, Mimoun G, Ruiz-Moreno JM, Quaranta-El Maftouhi M,
De Laey JJ, Postelmans L, Soubrane G, Defauchy M, Leys A. Verteporfin
photodynamic therapy for choroidal neovascularization associated with
toxoplasmic retinochoroiditis. Retina. 2006 Apr;26(4):396-403. PubMed
PMID: 16603957.
163: Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced
photodynamic therapy with half dose verteporfin for chronic central
serous chorioretinopathy: a short term pilot study. Br J Ophthalmol.
2006 Jul;90(7):869-74. Epub 2006 Apr 5. PubMed PMID: 16597666; PubMed
Central PMCID: PMC1857171.
164: Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal
triamcinolone acetonide combination therapy for occult choroidal
neovascularization in age-related macular degeneration. Am J Ophthalmol.
2006 Apr;141(4):638-45. PubMed PMID: 16564797.
165: Kaiser PK; Treatment of Age-Related Macular Degeneration with
Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal
choroidal neovascularization in age-related macular degeneration: 5-year
results of two randomized clinical trials with an open-label extension:
TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006
Sep;244(9):1132-42. Epub 2006 Mar 15. PubMed PMID: 16538452.
166: Yoon KC, Ahn KY, Lee SE, Kim KK, Im SK, Oh HJ, Jeong IY, Park SW,
Park YG, Nah HJ, Im WB. Experimental inhibition of corneal
neovascularization by photodynamic therapy with verteporfin. Curr Eye
Res. 2006 Mar;31(3):215-24. PubMed PMID: 16531278.
167: Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic
therapy with verteporfin for retinal angiomatous proliferation. Graefes
Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1224-32. Epub 2006 Mar 9.
PubMed PMID: 16525824.
168: Wickens J, Blinder KJ. A preliminary benefit-risk assessment of
verteporfin in age-related macular degeneration. Drug Saf.
2006;29(3):189-99. Review. PubMed PMID: 16524319.
169: Nicolň M, Ghiglione D, Lai S, Calabria G. Retinal angiomatous
proliferation treated by intravitreal triamcinolone and photodynamic
therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2006
Oct;244(10):1336-8. Epub 2006 Mar 8. PubMed PMID: 16523293.
170: Pece A, Vadalŕ M, Manzi R, Calori G. Back pain after photodynamic
therapy with verteporfin. Am J Ophthalmol. 2006 Mar;141(3):593-4. PubMed
PMID: 16490525.
171: Michels S, Aue A, Simader C, Geitzenauer W, Sacu S, Schmidt-Erfurth
U. Retinal pigment epithelium tears following verteporfin therapy
combined with intravitreal triamcinolone. Am J Ophthalmol. 2006
Feb;141(2):396-398. PubMed PMID: 16458709.
172: Nicolň M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G.
Occult with no classic choroidal neovascularization secondary to
age-related macular degeneration treated by intravitreal triamcinolone
and photodynamic therapy with verteporfin. Retina. 2006 Jan;26(1):58-64.
PubMed PMID: 16395140.
173: Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence
of treatment parameters on selectivity of verteporfin therapy. Invest
Ophthalmol Vis Sci. 2006 Jan;47(1):371-6. PubMed PMID: 16384987.
174: Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K,
Hafezi-Moghadam A, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW. Effect
of intravitreal injection of ranibizumab in combination with verteporfin
PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci.
2006 Jan;47(1):357-63. PubMed PMID: 16384985.
175: Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with
intravitreal triamcinolone in all types of choroidal neovascularization
due to age-related macular degeneration. Ophthalmology. 2006
Jan;113(1):14-22. Epub 2005 Dec 19. PubMed PMID: 16360209.
176: Bakri SJ, Sears JE, Singh AD. Transient closure of a retinal
capillary hemangioma with verteporfin photodynamic therapy. Retina. 2005
Dec;25(8):1103-4. PubMed PMID: 16340546.
177: Thoelen AM, Bernasconi PP, Buser F, Fierz AB, Messmer EP.
Magnification requirement after photodynamic therapy with verteporfin
for subfoveal predominantly classic choroidal neovascularization due to
age-related macular degeneration. Eur J Ophthalmol. 2005
Nov-Dec;15(6):768-73. PubMed PMID: 16329064.
178: Doshi AB, Moshfeghi DM, Jack RL. Anaphylactoid reaction after
verteporfin therapy. Am J Ophthalmol. 2005 Nov;140(5):936-7. PubMed
PMID: 16310483.
179: Michels S, Wachtlin J, Gamulescu MA, Heimann H, Prünte C, Inhoffen
W, Krebs I, Schmidt-Erfurth U. Comparison of early retreatment with the
standard regimen in verteporfin therapy of neovascular age-related
macular degeneration. Ophthalmology. 2005 Dec;112(12):2070-5. Epub 2005
Oct 12. PubMed PMID: 16225928.
180: Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ. Effect of
posterior juxtascleral triamcinolone acetonide on choroidal neovascular
growth after photodynamic therapy with verteporfin. Ophthalmology. 2005
Nov;112(11):1896-903. Epub 2005 Oct 7. PubMed PMID: 16214216.
181: Bressler NM, Bressler SB, Haynes LA, Hao Y, Kaiser PK, Miller JW,
Naor J, Potter MJ, Pournaras CJ, Reaves A, Rosenfeld PJ, Schmidt-Erfurth
U, Slakter JS, Strong A, Vannier S. Verteporfin therapy for subfoveal
choroidal neovascularization in age-related macular degeneration:
four-year results of an open-label extension of 2 randomized clinical
trials: TAP Report No. 7. Arch Ophthalmol. 2005 Sep;123(9):1283-5.
PubMed PMID: 16157822.
182: Samkoe KS, Fecica MS, Goyan RL, Buchholz JL, Campbell C, Kelly NM,
Cramb DT. Photobleaching kinetics of optically trapped multilamellar
vesicles containing verteporfin using two-photon excitation section
sign. Photochem Photobiol. 2006 Jan-Feb;82(1):152-7. PubMed PMID:
16149861.
183: Michels S, Michels R, Simader C, Schmidt-Erfurth U. Verteporfin
therapy for choroidal hemangioma: a long-term follow-up. Retina. 2005
Sep;25(6):697-703. PubMed PMID: 16141856.
184: Klais CM, Ober MD, Freund KB, Ginsburg LH, Luckie A, Mauget-Fa˙sse
M, Coscas G, Gross NE, Yannuzzi LA. Choroidal infarction following
photodynamic therapy with verteporfin. Arch Ophthalmol. 2005
Aug;123(8):1149-53. PubMed PMID: 16087856.
185: Gibson J. Photodynamic therapy with verteporfin for juxtafoveal
choroidal neovascularisation secondary to pathological myopia. Eye
(Lond). 2005 Aug;19(8):829-30. PubMed PMID: 16086038.
186: Tayanithi P, Pisankosakul P, Laksakapuk P. Treatment of subfoveal
choroidal neovascularization secondary to age related macular
degeneration with single treatment of verteporfin photodynamic therapy:
a safety and short-term outcome. J Med Assoc Thai. 2004 Sep;87 Suppl
2:S78-82. PubMed PMID: 16083167.
187: Szabó A, Géhl Z, Seres A. Photodynamic (verteporfin) therapy for
retinal capillary haemangioma, with monitoring of feeder and draining
blood vessel diameters. Acta Ophthalmol Scand. 2005 Aug;83(4):512-3.
PubMed PMID: 16029284.
188: Voelker M, Gelisken F, Ziemssen F, Wachtlin J, Grisanti S.
Verteporfin photodynamic therapy for extrafoveal choroidal
neovascularisation secondary to age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1241-6. Epub 2005 Jul
12. PubMed PMID: 16010552.
189: Kaiser PK. Verteporfin therapy in combination with triamcinolone:
published studies investigating a potential synergistic effect. Curr Med
Res Opin. 2005 May;21(5):705-13. Review. PubMed PMID: 15969870.
190: Hariprasad SM, Shah GK. Treatment of juxtafoveal choroidal
neovascularization with photodynamic therapy using verteporfin in eyes
with age-related macular degeneration. Ophthalmic Surg Lasers Imaging.
2005 May-Jun;36(3):258-60. PubMed PMID: 15957487.
191: Heimann H, Gelisken F, Wachtlin J, Wehner A, Völker M, Foerster MH,
Bartz-Schmidt KU. Photodynamic therapy with verteporfin for choroidal
neovascularization associated with angioid streaks. Graefes Arch Clin
Exp Ophthalmol. 2005 Nov;243(11):1115-23. Epub 2005 Jun 10. PubMed PMID:
15947939.
192: Browning AC, Chung AK, Ghanchi F, Harding SP, Musadiq M, Talks SJ,
Yang YC, Amoaku WM; United Kingdom PDT Users Group. Verteporfin
photodynamic therapy of choroidal neovascularization in angioid streaks:
one-year results of a prospective case series. Ophthalmology. 2005
Jul;112(7):1227-31. PubMed PMID: 15921757.
193: Chung AK, Gauba V, Ghanchi FD. Photodynamic therapy (PDT) using
verteporfin for juxtafoveal choroidal neovascularisation (CNV) in
angioid streaks (AS) associated with pseudoxanthoma elasticum: 40 months
results. Eye (Lond). 2006 May;20(5):629-31. PubMed PMID: 15920567.
194: Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR,
Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy
with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2005
Oct;243(10):973-9. Epub 2005 Oct 20. PubMed PMID: 15864616.
195: Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E,
Connolly EJ, Michaud N, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW.
Safety and efficacy of intravitreal injection of ranibizumab in
combination with verteporfin PDT on experimental choroidal
neovascularization in the monkey. Arch Ophthalmol. 2005
Apr;123(4):509-16. PubMed PMID: 15824225.
196: Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y,
Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld
PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC;
Visudyne in Minimally Classic Choroidal Neovascularization Study Group.
Verteporfin therapy of subfoveal minimally classic choroidal
neovascularization in age-related macular degeneration: 2-year results
of a randomized clinical trial. Arch Ophthalmol. 2005 Apr;123(4):448-57.
PubMed PMID: 15824216.
197: Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP, Myles R. Three
cases of large retinal capillary hemangiomas treated with verteporfin
and photodynamic therapy. Arch Ophthalmol. 2005 Mar;123(3):328-32.
PubMed PMID: 15767474.
198: Gupta R, Browning AC, Wu K, Sokal M, Amoaku WM. Verteporfin
photodynamic therapy for the treatment of persistent subfoveal choroidal
neovascularization after external beam radiotherapy: one-year results.
Am J Ophthalmol. 2005 Mar;139(3):561-2. PubMed PMID: 15767080.
199: Ladas ID, Georgalas I, Rouvas AA, Gotsis S, Karagiannis DA, Moschos
M. Photodynamic therapy with verteporfin of choroidal neovascularization
in angioid streaks: conventional versus early retreatment. Eur J
Ophthalmol. 2005 Jan-Feb;15(1):69-73. PubMed PMID: 15751242.
200: Arias L, Pujol O, Berniell J, Rubio M, Roca G, Castillo L, Acebes
E. Impact of lesion size on photodynamic therapy with verteporfin of
predominantly classic lesions in age related macular degeneration. Br J
Ophthalmol. 2005 Mar;89(3):312-5. PubMed PMID: 15722311; PubMed Central
PMCID: PMC1772570.
201: Konan-Kouakou YN, Boch R, Gurny R, Allémann E. In vitro and in vivo
activities of verteporfin-loaded nanoparticles. J Control Release. 2005
Mar 2;103(1):83-91. Epub 2005 Jan 11. PubMed PMID: 15710502.
202: Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with
verteporfin combined with intravitreal injection of triamcinolone
acetonide for choroidal neovascularization. Ophthalmology. 2005
Feb;112(2):301-4. PubMed PMID: 15691567.
203: Verteporfin Roundtable Participants. Guidelines for using
verteporfin (Visudyne) in photodynamic therapy for choroidal
neovascularization due to age-related macular degeneration and other
causes: update. Retina. 2005 Feb-Mar;25(2):119-34. Review. PubMed PMID:
15689800.
204: Wachtlin J, Stroux A, Wehner A, Heimann H, Foerster MH.
Photodynamic therapy with verteporfin for choroidal neovascularisations
in clinical routine outside the TAP study. One- and two-year results
including juxtafoveal and extrafoveal CNV. Graefes Arch Clin Exp
Ophthalmol. 2005 May;243(5):438-45. Epub 2004 Dec 11. PubMed PMID:
15672299.
205: Rosenblatt BJ, Shah GK, Blinder K. Photodynamic therapy with
verteporfin for peripapillary choroidal neovascularization. Retina. 2005
Jan;25(1):33-7. PubMed PMID: 15655438.
206: Meyer CH, Lapolice DJ, Fekrat S. Functional changes after
photodynamic therapy with verteporfin. Am J Ophthalmol. 2005
Jan;139(1):214-5. PubMed PMID: 15652863.
207: Schein OD, Bressler NM, Price P. Photodynamic therapy with
verteporfin: observations on the introduction of a new treatment into
clinical practice. Arch Ophthalmol. 2005 Jan;123(1):58-63. Erratum in:
Arch Ophthalmol. 2005 Apr;123(4):582. PubMed PMID: 15642813.
208: Frennesson CI. Photodynamic therapy with verteporfin in patients
with age-related macular degeneration and juxtafoveal choroidal
neovascularization. Acta Ophthalmol Scand. 2004 Dec;82(6):651-5. PubMed
PMID: 15606459.
209: Bandello F, Blinder K, Bressler NM, Brown AL, Miller JW, Potter MJ,
Pournaras C, Reaves A, Rosenfeld PJ, Slakter JS, Soubrane G, Strong HA,
Stur M; VIP Report No. 5 Writing Committee. Verteporfin in Photodynamic
Therapy: report no. 5. Ophthalmology. 2004 Nov;111(11):2144. PubMed
PMID: 15522385.
210: Hamon F, Goeminne P. Photodynamic therapy with verteporfin
following transpupillary thermotherapy for CNV evolving from an
initially occult to a predominantly classic form, in patients with AMD.
Semin Ophthalmol. 2001 Dec;16(4):223-32. PubMed PMID: 15513445.
211: Greiner RA. Cost of care for patients with age-related macular
degeneration in Switzerland and cost-effectiveness of treatment with
verteporfin therapy. Semin Ophthalmol. 2001 Dec;16(4):218-22. PubMed
PMID: 15513444.
212: Huber G, Levy J. Development of verteporfin therapy: a
collaboration between pharmaceutical companies, device manufacturers and
clinical investigators. Semin Ophthalmol. 2001 Dec;16(4):213-7. Review.
PubMed PMID: 15513443.
213: Sickenberg M. Verteporfin therapy for subfoveal choroidal
neovascularization in age-related macular degeneration: from clinical
trials to clinical practice. Semin Ophthalmol. 2001 Dec;16(4):207-12.
Review. PubMed PMID: 15513442.
214: Michels S, Schmidt-Erfurth U. Photodynamic therapy with
verteporfin: a new treatment in ophthalmology. Semin Ophthalmol. 2001
Dec;16(4):201-6. Review. PubMed PMID: 15513441.
215: Sickenberg M. Verteporfin therapy for choroidal neovascularization:
from concept to proof of efficacy. Semin Ophthalmol. 2001
Dec;16(4):177-80. PubMed PMID: 15513439.
216: Hussain N, Das T, Vashist U, Sumashri K. Verteporfin therapy for
myopic choroidal neovascularisation in Indian eyes (one year results).
Indian J Ophthalmol. 2004 Sep;52(3):227-31. PubMed PMID: 15510463.
217: Silva R, Torrent T, Loureiro R, Travassos A, de Abreu JR. Bilateral
CNV associated with optic nerve drusen treated with photodynamic therapy
with verteporfin. Eur J Ophthalmol. 2004 Sep-Oct;14(5):434-7. PubMed
PMID: 15506607.
218: Paskowitz DM, Nune G, Yasumura D, Yang H, Bhisitkul RB, Sharma S,
Matthes MT, Zarbin MA, Lavail MM, Duncan JL. BDNF reduces the retinal
toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci.
2004 Nov;45(11):4190-6. PubMed PMID: 15505074.
219: De Santis M, Carducci B, De Santis L, Lucchese A, Straface G. First
case of post-conception Verteporfin exposure: pregnancy and neonatal
outcome. Acta Ophthalmol Scand. 2004 Oct;82(5):623-4. PubMed PMID:
15453867.
220: Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK. Photodynamic
therapy with verteporfin for subfoveal choroidal neovascularisation of
pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year
follow up. Br J Ophthalmol. 2004 Oct;88(10):1315-9. PubMed PMID:
15377558; PubMed Central PMCID: PMC1772358.
221: Lam DS, Liu DT, Fan DS, Lai WW, So SF, Chan WM. Photodynamic
therapy with verteporfin for juxtafoveal choroidal neovascularization
secondary to pathologic myopia-1-year results of a prospective series.
Eye (Lond). 2005 Aug;19(8):834-40. PubMed PMID: 15375364.
222: Rosenfeld PJ, Saperstein DA, Bressler NM, Reaves TA, Sickenberg M,
Rosa RH Jr, Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr; Verteporfin in
Ocular Histoplasmosis Study Group. Photodynamic therapy with verteporfin
in ocular histoplasmosis: uncontrolled, open-label 2-year study.
Ophthalmology. 2004 Sep;111(9):1725-33. PubMed PMID: 15350329.
223: Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic
therapy with verteporfin for age related macular degeneration: the UK
case. Br J Ophthalmol. 2004 Sep;88(9):1107-12. PubMed PMID: 15317697;
PubMed Central PMCID: PMC1772332.
224: Isola V, Pece A, Brancato R. Circulatory changes in the choroidal
vasculature after verteporfin-based photodynamic therapy for choroidal
neovascularization in age-related macular degeneration. Retina. 2004
Aug;24(4):618-20. PubMed PMID: 15300088.
225: Bessler NM; Vam Study Writing Committee. Verteporfin therapy in
age-related macular degeneration (VAM): an open-label multicenter
photodynamic therapy study of 4,435 patients. Retina. 2004
Aug;24(4):512-20. Erratum in: Retina. 2004 Dec;24(6):990. PubMed PMID:
15300071.
226: Blair MP, Apte RS, Miskala PH, Bressler SB, Goldberg MF, Schachat
AP, Bressler NM. Retrospective case series of juxtafoveal choroidal
neovascularization treated with photodynamic therapy with verteporfin.
Retina. 2004 Aug;24(4):501-6. PubMed PMID: 15300069.
227: Parodi MB, Di Crecchio L, Lanzetta P, Polito A, Bandello F,
Ravalico G. Photodynamic therapy with verteporfin for subfoveal
choroidal neovascularization associated with multifocal choroiditis. Am
J Ophthalmol. 2004 Aug;138(2):263-9. PubMed PMID: 15289136.
228: Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH.
Photodynamic therapy with verteporfin for symptomatic polypoidal
choroidal vasculopathy: one-year results of a prospective case series.
Ophthalmology. 2004 Aug;111(8):1576-84. PubMed PMID: 15288991.
229: Gaynes BI, Fiscella RG. Safety of verteporfin for treatment of
subfoveal choroidal neovascular membranes associated with age-related
macular degeneration. Expert Opin Drug Saf. 2004 Jul;3(4):345-61.
Review. PubMed PMID: 15268651.
230: Taban M, Thomas EL, Boyer DS, Novack RL, Chu TG, Gallemore RP.
Efficacy of verteporfin photodynamic therapy on laser-induced choroidal
neovascularization and the ancillary effect on diabetic
microvasculopathy. Curr Eye Res. 2004 Apr;28(4):291-5. PubMed PMID:
15259299.
231: Gelisken F, Inhoffen W, Karim-Zoda K, Grisanti S, Partsch M,
Voelker M, Bartz-Schmidt KU. Subfoveal hemorrhage after verteporfin
photodynamic therapy in treatment of choroidal neovascularization.
Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):198-203. Epub 2004 Jul
17. PubMed PMID: 15258778.
232: Gelisken F, Inhoffen W, Hermann A, Grisanti S, Bartz-Schmidt KU.
Verteporfin photodynamic therapy for extrafoveal choroidal
neovascularisation in pathologic myopia. Graefes Arch Clin Exp
Ophthalmol. 2004 Nov;242(11):926-30. Epub 2004 Jul 17. PubMed PMID:
15258776.
233: Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller
JW. Selective photodynamic therapy by targeted verteporfin delivery to
experimental choroidal neovascularization mediated by a homing peptide
to vascular endothelial growth factor receptor-2. Arch Ophthalmol. 2004
Jul;122(7):1002-11. PubMed PMID: 15249365.
234: Parodi MB, Iacono P. Photodynamic therapy with verteporfin for
anterior segment neovascularizations in neovascular glaucoma. Am J
Ophthalmol. 2004 Jul;138(1):157-8. PubMed PMID: 15234305.
235: Sharma S, Bakal J, Oliver-Fernandez A, Blair J. Photodynamic
therapy with verteporfin for subfoveal choroidal neovascularization in
age-related macular degeneration: results of an effectiveness study.
Arch Ophthalmol. 2004 Jun;122(6):853-6. PubMed PMID: 15197060.
236: Nessi F, Guex-Crosier Y, Ambresin A, Zografos L. Photodynamic
therapy with verteporfin for subfoveal choroidal neovascularization
secondary to toxoplasmic chorioretinal scar. Klin Monbl Augenheilkd.
2004 May;221(5):371-3. PubMed PMID: 15162283.
237: Soucek P, Cihelková I. Evaluation of subretinal fluid absorption by
optical coherence tomography in circumscribed choroidal hemangioma after
photodynamic therapy with Verteporfin. Neuro Endocrinol Lett. 2004
Feb-Apr;25(1-2):109-14. PubMed PMID: 15159693.
238: Zhou X, Pogue BW, Chen B, Hasan T. Analysis of effective molecular
diffusion rates for verteporfin in subcutaneous versus orthotopic
Dunning prostate tumors. Photochem Photobiol. 2004 Apr;79(4):323-31.
PubMed PMID: 15137508.
239: Grisanti S, Tatar O, Canbek S, Lafaut BA, Gelisken F, Inhoffen W,
Szurman P, Aisenbrey S, Oficjalska-Mlynczak J, Bartz-Schmidt KU.
Immunohistopathologic evaluation of choroidal neovascular membranes
following verteporfin-photodynamic therapy. Am J Ophthalmol. 2004
May;137(5):914-23. PubMed PMID: 15126158.
240: Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels
SM. Effects of verteporfin therapy on central visual field function.
Ophthalmology. 2004 May;111(5):931-9. PubMed PMID: 15121371.
241: Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy
with verteporfin for polypoidal choroidal vasculopathy of the macula.
Ophthalmologica. 2004 May-Jun;218(3):193-201. PubMed PMID: 15103216.
242: Fossarello M, Peiretti E, Zucca I, Perra MT, Serra A. Photodynamic
therapy of pterygium with verteporfin: a preliminary report. Cornea.
2004 May;23(4):330-8. PubMed PMID: 15097125.
243: Bains HS, Cirino AC, Ticho BH, Jampol LM. Photodynamic therapy
using verteporfin for a diffuse choroidal hemangioma in Sturge-Weber
syndrome. Retina. 2004 Feb;24(1):152-5. PubMed PMID: 15076958.
244: Ergun E, Zawinka C, Stur M. Incidence of laser photocoagulation and
photodynamic therapy with verteporfin at a tertiary retinal center.
Retina. 2004 Feb;24(1):13-8. PubMed PMID: 15076938.
245: Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB,
Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U, Miller JW,
Mones J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A, Su XY, Slakter JS,
Schmidt-Erfurth U, Sorenson JA; Treatment of Age-Related Macular
Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in
Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal
choroidal neovascularization in age-related macular degeneration:
meta-analysis of 2-year safety results in three randomized clinical
trials: Treatment Of Age-Related Macular Degeneration With Photodynamic
Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
Retina. 2004 Feb;24(1):1-12. PubMed PMID: 15076937.
246: Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes
L, Lim JI, Miller JW, Potter MJ, Reaves A, Rosenfeld PJ, Sickenberg M,
Slakter JS, Soubrane G, Strong HA, Stur M; Treatment of Age-Related
Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin
in Photodynamic Therapy Study Group. Acute severe visual acuity decrease
after photodynamic therapy with verteporfin: case reports from
randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol.
2004 Apr;137(4):683-96. PubMed PMID: 15059708.
247: Verteporfin: new indication. In certain age-related macular
degeneration: too little evidence. Prescrire Int. 2004 Feb;13(69):7-9.
PubMed PMID: 15055207.
248: Huang Y, Obana A, Gohto Y, Nakajima S. Comparative study of the
phototoxicity of two chrolin type photosensitizers, ATX-S10(Na) and
verteporfin, on vascular endothelial and retinal pigment epithelial
cells. Lasers Surg Med. 2004;34(3):216-26. PubMed PMID: 15022248.
249: Do DV, Bressler NM, Bressler SB. Large submacular hemorrhages after
verteporfin therapy. Am J Ophthalmol. 2004 Mar;137(3):558-60. PubMed
PMID: 15013883.
250: Keam SJ, Scott LJ, Curran MP. Spotlight on verteporfin in subfoveal
choroidal neovascularisation. Drugs Aging. 2004;21(3):203-9. Review.
PubMed PMID: 14979737.
251: Yang YC. Preserving vision with verteporfin photodynamic therapy.
Hosp Med. 2004 Jan;65(1):39-43. Review. PubMed PMID: 14964795.
252: Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in
verteporfin photodynamic therapy for choroidal
neovascularisation--'beyond the TAP study'. Eye (Lond). 2004
Aug;18(8):809-13. PubMed PMID: 14963483.
253: Karadimas P, Bouzas EA. Photodynamic therapy with verteporfin for
choroidal neovascularization complicating angioid streaks. Ophthalmic
Surg Lasers Imaging. 2004 Jan-Feb;35(1):78-80. PubMed PMID: 14750772.
254: Arevalo JF, Ruiz-Moreno JM, Fernandez CF, Mendoza AJ, Ramirez E,
Montero JA. Photodynamic therapy with verteporfin for subfoveal
choroidal neovascular membranes in highly myopic eyes after laser in
situ keratomileusis. Ophthalmic Surg Lasers Imaging. 2004
Jan-Feb;35(1):58-62. PubMed PMID: 14750766.
255: Schattner A, Pollack A. Verteporfin and myocardial infarction. Ann
Pharmacother. 2004 Feb;38(2):352. Epub 2003 Dec 19. PubMed PMID:
14742780.
256: Meads C, Hyde C. Photodynamic therapy with verteporfin is
effective, but how big is its effect? Results of a systematic review. Br
J Ophthalmol. 2004 Feb;88(2):212-7. Review. PubMed PMID: 14736777;
PubMed Central PMCID: PMC1772007.
257: Gelisken F, Lafaut BA, Inhoffen W, Voelker M, Grisanti S,
Bartz-Schmidt KU. Clinicopathological findings of choroidal
neovascularisation following verteporfin photodynamic therapy. Br J
Ophthalmol. 2004 Feb;88(2):207-11. PubMed PMID: 14736776; PubMed Central
PMCID: PMC1771999.
258: Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, Chan A,
Neyndorff H, Su XY, Jain H, Hamzavi I, McLean D, Bissonnette R.
Photodynamic therapy of multiple nonmelanoma skin cancers with
verteporfin and red light-emitting diodes: two-year results evaluating
tumor response and cosmetic outcomes. Arch Dermatol. 2004
Jan;140(1):26-32. PubMed PMID: 14732656.
259: Ergun E, Tittl M, Stur M. Photodynamic therapy with verteporfin in
subfoveal choroidal neovascularization secondary to central serous
chorioretinopathy. Arch Ophthalmol. 2004 Jan;122(1):37-41. PubMed PMID:
14718292.
260: Bakri SJ, Kaiser PK. Verteporfin ocular photodynamic therapy.
Expert Opin Pharmacother. 2004 Jan;5(1):195-203. Review. PubMed PMID:
14680447.
261: Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal
vascular remodelling in central serous chorioretinopathy after
indocyanine green guided photodynamic therapy with verteporfin: a novel
treatment at the primary disease level. Br J Ophthalmol. 2003
Dec;87(12):1453-8. PubMed PMID: 14660450; PubMed Central PMCID:
PMC1920573.
262: Andrade RE, Farah ME, Costa RA. Photodynamic therapy with
verteporfin for subfoveal choroidal neovascularization in best disease.
Am J Ophthalmol. 2003 Dec;136(6):1179-81. PubMed PMID: 14644242.
263: Essex RW, Qureshi SH, Cain MS, Harper CA, Guymer RH. Photodynamic
therapy in practice: a review of the results of the first 12 months
experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
Clin Experiment Ophthalmol. 2003 Dec;31(6):476-81. PubMed PMID:
14641153.
264: Chan WM, Lam DS, Wong TH, Lai TY, Kwok AK, Tam BS, Li KK.
Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal
neovascularization: one-year results from a prospective case series.
Ophthalmology. 2003 Dec;110(12):2395-402. PubMed PMID: 14644724.
265: Japanese Age-Related Macular Degeneration Tial (JAT) Study Group.
Japanese age-related macular degeneration trial: 1-year results of
photodynamic therapy with verteporfin in Japanese patients with
subfoveal choroidal neovascularization secondary to age-related macular
degeneration. Am J Ophthalmol. 2003 Dec;136(6):1049-61. PubMed PMID:
14644215.
266: Bakri SJ, Beer PM. Photodynamic therapy with verteporfin for
classic choroidal neovascularization secondary to focal laser
photocoagulation for radiation retinopathy. Ophthalmic Surg Lasers
Imaging. 2003 Nov-Dec;34(6):475-7. PubMed PMID: 14620753.
267: Keam SJ, Scott LJ, Curran MP. Verteporfin : a review of its use in
the management of subfoveal choroidal neovascularisation. Drugs.
2003;63(22):2521-54. Review. PubMed PMID: 14609361.
268: Chan WM, Lam DS, Lai TY, Yuen KS, Liu DT, Chan CK, Chen WQ.
Treatment of choroidal neovascularization in central serous
chorioretinopathy by photodynamic therapy with verteporfin. Am J
Ophthalmol. 2003 Nov;136(5):836-45. PubMed PMID: 14597034.
269: Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results
after photodynamic therapy with verteporfin for choroidal
neovascularizations secondary to inflammatory chorioretinal diseases.
Graefes Arch Clin Exp Ophthalmol. 2003 Nov;241(11):899-906. Epub 2003
Oct 11. PubMed PMID: 14556077.
270: Nicolň M, Ghiglione D, Polizzi A, Calabria G. Choroidal hemangioma
treated with photodynamic therapy using verteporfin: report of a case.
Eur J Ophthalmol. 2003 Aug-Sep;13(7):656-61. PubMed PMID: 14552602.
271: Chen B, Pogue BW, Goodwin IA, O'Hara JA, Wilmot CM, Hutchins JE,
Hoopes PJ, Hasan T. Blood flow dynamics after photodynamic therapy with
verteporfin in the RIF-1 tumor. Radiat Res. 2003 Oct;160(4):452-9.
PubMed PMID: 12968929.
272: Chan WM, Li KK, Liu DT, Lai TY, Chong KK, Lam DS. Photodynamic
therapy with verteporfin in laser-induced choroidal neovascularization.
Am J Ophthalmol. 2003 Sep;136(3):565-7. PubMed PMID: 12967823.
273: Sawa M, Chan WM, Ohji M, Imai K, Fujikado T, Tano Y, Schachat AP.
Successful photodynamic therapy with verteporfin for recurrent choroidal
neovascularization beneath the new fovea after macular translocation
surgery with 360-degree retinotomy. Am J Ophthalmol. 2003
Sep;136(3):560-3. PubMed PMID: 12967821.
274: Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y,
Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld
PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-related
Macular Degeneration with Photodynamic Therapy study group; Verteporfin
in Photodynamic Therapy study group. Effect of lesion size, visual
acuity, and lesion composition on visual acuity change with and without
verteporfin therapy for choroidal neovascularization secondary to
age-related macular degeneration: TAP and VIP report no. 1. Am J
Ophthalmol. 2003 Sep;136(3):407-18. PubMed PMID: 12967792.
275: Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L,
Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P,
Schachat AP, Strong HA, Wenkstern A; Treatment of Age-Related Macular
Degeneration with Photodynamic Therapy Study Group; Verteporfin in
Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal
choroidal neovascularization with verteporfin: fluorescein angiographic
guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch
Ophthalmol. 2003 Sep;121(9):1253-68. PubMed PMID: 12963608.
276: Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy
with verteporfin and intravitreal triamcinolone acetonide for choroidal
neovascularization. Ophthalmology. 2003 Aug;110(8):1517-25. PubMed PMID:
12917166.
277: Hershberger VS, Hutchins RK, Laber PW. Photodynamic therapy with
verteporfin for subretinal neovascularization secondary to bilateral
idiopathic acquired juxtafoveolar telangiectasis. Ophthalmic Surg Lasers
Imaging. 2003 Jul-Aug;34(4):318-20. PubMed PMID: 12875464.
278: Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine
green angiography through two years after photodynamic therapy with
verteporfin. Ophthalmology. 2003 Jul;110(7):1306-14. PubMed PMID:
12867383.
279: Fossarello M, Peiretti E, Zucca I, Serra A. Photodynamic therapy of
corneal neovascularization with verteporfin. Cornea. 2003
Jul;22(5):485-8. PubMed PMID: 12827058.
280: Busquets MA, Shah GK, Wickens J, Callanan D, Blinder KJ, Burgess D,
Grand MG, Holekamp NM, Boniuk I, Joseph DP, Thomas MA, Fish E, Bakal J,
Hollands H, Sharma S. Ocular photodynamic therapy with verteporfin for
choroidal neovascularization secondary to ocular histoplasmosis
syndrome. Retina. 2003 Jun;23(3):299-306. PubMed PMID: 12824828.
281: Holzer MP, Solomon KD, Vroman DT, Sandoval HP, Margaron P, Kasper
TJ, Crosson CE. Photodynamic therapy with verteporfin in a rabbit model
of corneal neovascularization. Invest Ophthalmol Vis Sci. 2003
Jul;44(7):2954-8. PubMed PMID: 12824237.
282: Lees MJ, Aldridge GJ, Davey PJ, Gorgievski M. Economic evaluation
of photodynamic therapy with verteporfin. Ophthalmology. 2003
Jun;110(6):1263-4; author reply 1264-5. PubMed PMID: 12799261.
283: Mimouni KF, Bressler SB, Bressler NM. Photodynamic therapy with
verteporfin for subfoveal choroidal neovascularization in children. Am J
Ophthalmol. 2003 Jun;135(6):900-2. PubMed PMID: 12788138.
284: Savellano MD, Hasan T. Targeting cells that overexpress the
epidermal growth factor receptor with polyethylene glycolated BPD
verteporfin photosensitizer immunoconjugates. Photochem Photobiol. 2003
Apr;77(4):431-9. PubMed PMID: 12733655.
285: Tan W, Beaumont PE, Chang AA. Case series outcomes at 1 week
following verteporfin photodynamic therapy. Retina. 2003
Apr;23(2):166-70. PubMed PMID: 12707594.
286: Casas A, Di Venosa G, Batlle A, Fukuda H. In vitro
photosensitisation of a murine mammary adenocarcinoma cell line with
Verteporfin. Cell Mol Biol (Noisy-le-grand). 2002 Dec;48(8):931-7.
PubMed PMID: 12699253.
287: Aquaron R, Forzano O, Murati JL, Fayet G, Aquaron C, Ridings B.
Simple, reliable and fast spectrofluorometric method for determination
of plasma Verteporfin (Visudyne) levels during photodynamic therapy for
choroidal neovascularization. Cell Mol Biol (Noisy-le-grand). 2002
Dec;48(8):925-30. Erratum in: Cell Mol Biol (Noisy-le-grand). 2003
Feb;49(1):123. PubMed PMID: 12699252.
288: Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G,
Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras
C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M,
Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Verteporfin
therapy of subfoveal choroidal neovascularization in pathologic myopia:
2-year results of a randomized clinical trial--VIP report no. 3.
Ophthalmology. 2003 Apr;110(4):667-73. PubMed PMID: 12689884.
289: Lees MJ, Aldridge GJ, Davey PJ, Gorgievski M. Economic evaluation
of photodynamic therapy with verteporfin. Ophthalmology. 2003
Apr;110(4):626-7; author reply 627-8. Corrected and republished in:
Ophthalmology. 2003 Jun;110(6):1263-4; author reply 1264-5. PubMed PMID:
12689865.
290: Spaide RF, Maranan L. Neutrophil margination as a possible
mechanism for verteporfin infusion-associated pain. Am J Ophthalmol.
2003 Apr;135(4):549-50. PubMed PMID: 12654380.
291: Harding S. Verteporfin photodynamic therapy in the UK: implications
of the NICE appraisal. Eye (Lond). 2003 Mar;17(2):119-22. PubMed PMID:
12640394.
292: Anand R, Bressler NM, Bressler SB, Gray TE, Harvey P, Haynes L,
Koester JM, Manos KS, Miller JW, Murphy S, Reaves A, Sickenberg M,
Singerman LJ, Strong A, Stur M; "Improvement After Verteporfin Therapy"
Writting Committee for TAP Study Group. Improvement after verteporfin
therapy. Arch Ophthalmol. 2003 Mar;121(3):415-6. PubMed PMID: 12617718.
293: Pogue BW, O'Hara JA, Demidenko E, Wilmot CM, Goodwin IA, Chen B,
Swartz HM, Hasan T. Photodynamic therapy with verteporfin in the
radiation-induced fibrosarcoma-1 tumor causes enhanced radiation
sensitivity. Cancer Res. 2003 Mar 1;63(5):1025-33. PubMed PMID:
12615718.
294: Moshfeghi DM, Kaiser PK, Grossniklaus HE, Sternberg P Jr, Sears JE,
Johnson MW, Ratliff N, Branco A, Blumenkranz MS, Lewis H.
Clinicopathologic study after submacular removal of choroidal
neovascular membranes treated with verteporfin ocular photodynamic
therapy. Am J Ophthalmol. 2003 Mar;135(3):343-50. PubMed PMID: 12614752.
295: Chest pain on verteporfin. Prescrire Int. 2003 Feb;12(63):17.
PubMed PMID: 12602378.
296: Verteporfin: new indication. New indication in complications of
high myopia: no sustained benefit. Prescrire Int. 2003 Feb;12(63):5-8.
PubMed PMID: 12602372.
297: Müller VA, Ruokonen P, Schellenbeck M, Hartmann C, Tetz M.
Treatment of rubeosis iridis with photodynamic therapy with
verteporfin--A new therapeutic and prophylactic option for patients with
the risk of neovascular glaucoma? Ophthalmic Res. 2003
Jan-Feb;35(1):60-4. PubMed PMID: 12566865.
298: Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in
highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol.
2003 Feb;87(2):173-6. PubMed PMID: 12543746; PubMed Central PMCID:
PMC1771483.
299: Shaikh S, Ruby AJ, Williams GA. Photodynamic therapy using
verteporfin for choroidal neovascularization in angioid streaks. Am J
Ophthalmol. 2003 Jan;135(1):1-6. PubMed PMID: 12504689.
300: Jurklies B, Anastassiou G, Ortmans S, Schüler A, Schilling H,
Schmidt-Erfurth U, Bornfeld N. Photodynamic therapy using verteporfin in
circumscribed choroidal haemangioma. Br J Ophthalmol. 2003
Jan;87(1):84-9. PubMed PMID: 12488269; PubMed Central PMCID: PMC1771447.
301: Houle JM, Strong HA. Duration of skin photosensitivity and
incidence of photosensitivity reactions after administration of
verteporfin. Retina. 2002 Dec;22(6):691-7. PubMed PMID: 12476093.
302: Kang SW, Kang SJ, Kim HO, Nam ES, Lee JH, Koh HJ. Photodynamic
therapy using verteporfin-induced minimal change nephrotic syndrome. Am
J Ophthalmol. 2002 Dec;134(6):907-8. PubMed PMID: 12470762.
303: Srivastava SK, Sternberg P Jr. Retinal pigment epithelial tear
weeks following photodynamic therapy with verteporfin for choroidal
neovascularization secondary to pathologic myopia. Retina. 2002
Oct;22(5):669-71. PubMed PMID: 12441742.
304: Rubin GS, Bressler NM; Treatment of Age-Related Macular
Degeneration with Photodynamic therapy (TAP) study group. Effects of
verteporfin therapy on contrast on sensitivity: Results From the
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy
(TAP) investigation-TAP report No 4. Retina. 2002 Oct;22(5):536-44.
PubMed PMID: 12441717.
305: Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE,
Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos
K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of
Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study
Group. Verteporfin therapy of subfoveal choroidal neovascularization in
patients with age-related macular degeneration: additional information
regarding baseline lesion composition's impact on vision outcomes-TAP
report No. 3. Arch Ophthalmol. 2002 Nov;120(11):1443-54. PubMed PMID:
12427056.
306: Atebara NH. Retinal capillary hemangioma treated with verteporfin
photodynamic therapy. Am J Ophthalmol. 2002 Nov;134(5):788-90. PubMed
PMID: 12429270.
307: Sawa M, Ohji M, Gomi F, Kusaka S, Tano Y, Bressler NM. Apparent
disappearance of choroidal neovascularization after initial photodynamic
therapy with verteporfin. Arch Ophthalmol. 2002 Nov;120(11):1588-90.
PubMed PMID: 12427082.
308: Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes
LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A,
Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman
LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular
Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin
therapy for subfoveal choroidal neovascularization in age-related
macular degeneration: three-year results of an open-label extension of 2
randomized clinical trials--TAP Report no. 5. Arch Ophthalmol. 2002
Oct;120(10):1307-14. PubMed PMID: 12365909.
309: Karacorlu M, Karacorlu S, Ozdemir H, Mat C. Photodynamic therapy
with verteporfin for choroidal neovascularization in patients with
angioid streaks. Am J Ophthalmol. 2002 Sep;134(3):360-6. PubMed PMID:
12208247.
310: Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH Jr, Sickenberg M,
Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr, Reaves TA; Verteporfin in
Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of
subfoveal choroidal neovascularization with verteporfin in the ocular
histoplasmosis syndrome: one-year results of an uncontrolled,
prospective case series. Ophthalmology. 2002 Aug;109(8):1499-505. PubMed
PMID: 12153802.
311: Cahill MT, Smith BT, Fekrat S. Adverse reaction characterized by
chest pain, shortness of breath, and syncope associated with verteporfin
(visudyne). Am J Ophthalmol. 2002 Aug;134(2):281-2. PubMed PMID:
12140044.
312: Quaranta M, Mauget-Fa˙sse M, Coscas G. Exudative idiopathic
polypoidal choroidal vasculopathy and photodynamic therapy with
verteporfin. Am J Ophthalmol. 2002 Aug;134(2):277-80. PubMed PMID:
12140043.
313: Farah ME, Costa RA, Muccioli C, Guia TA, Belfort R Jr. Photodynamic
therapy with verteporfin for subfoveal choroidal neovascularization in
Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2002 Jul;134(1):137-9.
PubMed PMID: 12095828.
314: Jampol LM, Scott L. Treatment of juxtafoveal and extrafoveal
choroidal neovascularization in the era of photodynamic therapy with
verteporfin. Am J Ophthalmol. 2002 Jul;134(1):99-101. PubMed PMID:
12095815.
315: Spaide RF, Martin ML, Slakter J, Yannuzzi LA, Sorenson J, Guyer DR,
Freund KB. Treatment of idiopathic subfoveal choroidal neovascular
lesions using photodynamic therapy with verteporfin. Am J Ophthalmol.
2002 Jul;134(1):62-8. PubMed PMID: 12095809.
316: Zacks DN, Ezra E, Terada Y, Michaud N, Connolly E, Gragoudas ES,
Miller JW. Verteporfin photodynamic therapy in the rat model of
choroidal neovascularization: angiographic and histologic
characterization. Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2384-91.
PubMed PMID: 12091441.
317: Tornambe PE. Using intravenous diphenhydramine to minimize back
pain associated with photodynamic therapy with verteporfin. Arch
Ophthalmol. 2002 Jun;120(6):872. PubMed PMID: 12049608.
318: Ruiz-Oliva F, Cortés J. Verteporfin in Photodynamic Therapy (VIP)
Study group. Ophthalmology. 2002 Jun;109(6):1043; author reply 1043-4.
PubMed PMID: 12045040.
319: Jonas JB. Verteporfin therapy of subfoveal choroidal
neovascularization in age-related macular degeneration. Am J Ophthalmol.
2002 Jun;133(6):857; author reply 857-9. PubMed PMID: 12036694.
320: Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J
Clin Pharmacol. 2002 May;42(5):547-57. PubMed PMID: 12017349.
321: Zeng H, Korbelik M, McLean DI, MacAulay C, Lui H. Monitoring
photoproduct formation and photobleaching by fluorescence spectroscopy
has the potential to improve PDT dosimetry with a verteporfin-like
photosensitizer. Photochem Photobiol. 2002 Apr;75(4):398-405. PubMed
PMID: 12003130.
322: Verteporfin Roundtable 2000 and 2001 Participants; Treatment of
age-related macular degeneration with photodynamic therapy (TAP) study
group principal investigators; Verteporfin in photodynamic therapy (VIP)
study group principal investigators. Guidelines for using verteporfin
(visudyne) in photodynamic therapy to treat choroidal neovascularization
due to age-related macular degeneration and other causes. Retina. 2002
Feb;22(1):6-18. Review. PubMed PMID: 11884872.
323: Panjehpour M, DeNovo RC, Petersen MG, Overholt BF, Bower R,
Rubinchik V, Kelly B. Photodynamic therapy using Verteporfin
(benzoporphyrin derivative monoacid ring A, BPD-MA) and 630 nm laser
light in canine esophagus. Lasers Surg Med. 2002;30(1):26-30. PubMed
PMID: 11857600.
324: Dantas MA, Slakter JS, Negrao S, Fonseca RA, Kaga T, Yannuzzi LA.
Photodynamic therapy with verteporfin in mallatia leventinese.
Ophthalmology. 2002 Feb;109(2):296-301. PubMed PMID: 11825812.
325: Borodoker N, Spaide RF, Maranan L, Murray J, Freund KB, Slakter JS,
Sorenson JA, Yannuzzi LA, Guyer DR, Fisher YL. Verteporfin
infusion-associated pain. Am J Ophthalmol. 2002 Feb;133(2):211-4. PubMed
PMID: 11812424.
326: Mandal N, Chisholm IH. Identifying the proportion of age related
macular degeneration patients who would benefit from photodynamic
therapy with verteporfin (Visudyne). Br J Ophthalmol. 2002
Jan;86(1):118-9. PubMed PMID: 11801521; PubMed Central PMCID:
PMC1770961.
327: Messmer KJ, Abel SR. Verteporfin for age-related macular
degeneration. Ann Pharmacother. 2001 Dec;35(12):1593-8. Review. PubMed
PMID: 11793628.
328: Bressler NM. Verteporfin therapy of subfoveal choroidal
neovascularization in age-related macular degeneration: two-year results
of a randomized clinical trial including lesions with occult with no
classic choroidal neovascularization-verteporfin in photodynamic therapy
report 2. Am J Ophthalmol. 2002 Jan;133(1):168-9. PubMed PMID: 11755871.
329: Pogue BW, Braun RD, Lanzen JL, Erickson C, Dewhirst MW. Analysis of
the heterogeneity of pO2 dynamics during photodynamic therapy with
verteporfin. Photochem Photobiol. 2001 Nov;74(5):700-6. PubMed PMID:
11723798.
330: Verteporfin: new preparation. In combination with laser therapy:
helpful in some forms of age-related macular degeneration. Prescrire
Int. 2001 Jun;10(53):78-81. PubMed PMID: 11718169.
331: Madreperla SA. Choroidal hemangioma treated with photodynamic
therapy using verteporfin. Arch Ophthalmol. 2001 Nov;119(11):1606-10.
PubMed PMID: 11709010.
332: Ladd BS, Solomon SD, Bressler NM, Bressler SB. Photodynamic therapy
with verteporfin for choroidal neovascularization in patients with
diabetic retinopathy. Am J Ophthalmol. 2001 Nov;132(5):659-67. PubMed
PMID: 11704027.
333: Sharma S. Ophthaproblem. Photodynamic therapy with verteporfin. Can
Fam Physician. 2001 May;47:955, 963. PubMed PMID: 11398726; PubMed
Central PMCID: PMC2018487.
334: Verteporfin In Photodynamic Therapy Study Group. Verteporfin
therapy of subfoveal choroidal neovascularization in age-related macular
degeneration: two-year results of a randomized clinical trial including
lesions with occult with no classic choroidal
neovascularization--verteporfin in photodynamic therapy report 2. Am J
Ophthalmol. 2001 May;131(5):541-60. PubMed PMID: 11336929.
335: Brown SB, Mellish KJ. Verteporfin: a milestone in opthalmology and
photodynamic therapy. Expert Opin Pharmacother. 2001 Feb;2(2):351-61.
Review. PubMed PMID: 11336591.
336: Can [symbol: see text] verteporfin help in macular degeneration?
Drug Ther Bull. 2001 Apr;39(4):30-2. Review. PubMed PMID: 11329798.
337: Verteporfin in Photodynamic Therapy Study Group. Photodynamic
therapy of subfoveal choroidal neovascularization in pathologic myopia
with verteporfin. 1-year results of a randomized clinical trial--VIP
report no. 1. Ophthalmology. 2001 May;108(5):841-52. PubMed PMID:
11320011.
338: Soubrane G, Bressler NM. Treatment of subfoveal choroidal
neovascularisation in age related macular degeneration: focus on
clinical application of verteporfin photodynamic therapy. Br J
Ophthalmol. 2001 Apr;85(4):483-95. Review. PubMed PMID: 11264143; PubMed
Central PMCID: PMC1723921.
339: Belzacq AS, Jacotot E, Vieira HL, Mistro D, Granville DJ, Xie Z,
Reed JC, Kroemer G, Brenner C. Apoptosis induction by the
photosensitizer verteporfin: identification of mitochondrial adenine
nucleotide translocator as a critical target. Cancer Res. 2001 Feb
15;61(4):1260-4. PubMed PMID: 11245415.
340: Photodynamic therapy with verteporfin for age-related macular
degeneration. American Academy of Ophthalmology. Ophthalmology. 2000
Dec;107(12):2314-7. PubMed PMID: 11186878.
341: Bressler NM; Treatment of Age-Related Macular Degeneration with
Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of
subfoveal choroidal neovascularization in age-related macular
degeneration with verteporfin: two-year results of 2 randomized clinical
trials-tap report 2. Arch Ophthalmol. 2001 Feb;119(2):198-207. PubMed
PMID: 11176980.
342: Noffke AS, Jampol LM, Weinberg DV, Muńana A. A potentially
life-threatening adverse reaction to verteporfin. Arch Ophthalmol. 2001
Jan;119(1):143. PubMed PMID: 11146745.
343: Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic
therapy with verteporfin for the treatment of age-related macular
degeneration. Surv Ophthalmol. 2000 Nov-Dec;45(3):195-214. Review.
PubMed PMID: 11094244.
344: Photodynamic therapy with verteporfin (Visudyne) for macular
degeneration. Med Lett Drugs Ther. 2000 Sep 4;42(1086):81-2. PubMed
PMID: 10980812.
345: Margherio RR, Margherio AR, DeSantis ME. Laser treatments with
verteporfin therapy and its potential impact on retinal practices.
Retina. 2000;20(4):325-30. Review. PubMed PMID: 10950407.
346: Turnbull RG, Chen JC, Labow RS, Margaron P, Hsiang YN.
Benzoporphyrin derivative monacid ring A (Verteporfin) alone has no
inhibitory effect on intimal hyperplasia: in vitro and in vivo results.
J Invest Surg. 2000 May-Jun;13(3):153-9. PubMed PMID: 10933111.
347: Scott LJ, Goa KL. Verteporfin. Drugs Aging. 2000 Feb;16(2):139-46;
discussion 147-8. Review. PubMed PMID: 10755329.
348: Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos
L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM,
Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M,
Bressler NM. A preliminary study of photodynamic therapy using
verteporfin for choroidal neovascularization in pathologic myopia,
ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
Arch Ophthalmol. 2000 Mar;118(3):327-36. PubMed PMID: 10721954.
349: Bressler NM, Bressler SB. Photodynamic therapy with verteporfin
(Visudyne): impact on ophthalmology and visual sciences. Invest
Ophthalmol Vis Sci. 2000 Mar;41(3):624-8. Review. PubMed PMID: 10711673.
350: Granville DJ, Carthy CM, Jiang H, Levy JG, McManus BM, Matroule JY,
Piette J, Hunt DW. Nuclear factor-kappaB activation by the
photochemotherapeutic agent verteporfin. Blood. 2000 Jan 1;95(1):256-62.
PubMed PMID: 10607710.
351: Fine SL. Photodynamic therapy with verteporfin is effective for
selected patients with neovascular age-related macular degeneration.
Arch Ophthalmol. 1999 Oct;117(10):1400-2. Review. PubMed PMID: 10532450.
352: Photodynamic therapy of subfoveal choroidal neovascularization in
age-related macular degeneration with verteporfin: one-year results of 2
randomized clinical trials--TAP report. Treatment of age-related macular
degeneration with photodynamic therapy (TAP) Study Group. Arch
Ophthalmol. 1999 Oct;117(10):1329-45. Erratum in: Arch Ophthalmol 2000
Apr;118(4):488. PubMed PMID: 10532441.
353: Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES,
Miller JW. Verteporfin photodynamic therapy retreatment of normal retina
and choroid in the cynomolgus monkey. Ophthalmology. 1999
Oct;106(10):1915-23. PubMed PMID: 10519585.
354: Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I,
Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM,
Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M,
Bressler NM. Photodynamic therapy with verteporfin for choroidal
neovascularization caused by age-related macular degeneration: results
of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999
Sep;117(9):1177-87. Erratum in: Arch Ophthalmol 2000 Apr;118(4):488.
PubMed PMID: 10496389.
355: Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H,
Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van
den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM,
Gragoudas ES. Photodynamic therapy with verteporfin for choroidal
neovascularization caused by age-related macular degeneration: results
of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999
Sep;117(9):1161-73. Erratum in: Arch Ophthalmol 2000 Apr;118(4):488.
PubMed PMID: 10496388.
356: Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES,
Miller JW. Effects of photodynamic therapy using verteporfin on
experimental choroidal neovascularization and normal retina and choroid
up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999
Sep;40(10):2322-31. PubMed PMID: 10476799.
357: Chowdhary RK, Ratkay LG, Canaan AJ, Waterfield JD, Richter AM, Levy
JG. Uptake of verteporfin by articular tissues following systemic and
intra-articular administration. Biopharm Drug Dispos. 1998
Sep;19(6):395-400. PubMed PMID: 9737820.
358: Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ,
Gragoudas ES. Liposomal benzoporphyrin derivative verteporfin
photodynamic therapy. Selective treatment of choroidal
neovascularization in monkeys. Ophthalmology. 1996 Mar;103(3):427-38.
PubMed PMID: 8600419.
359: Labow RS, Higginson LA, Irvine J, Keaney M, Masters RG, Marquis JF,
Meek E, Mussivand T, Walley VM, Logan P, et al. Assessment of the
cytotoxicity of the photosensitizing drug BPD verteporfin using human
vascular smooth muscle cells in culture. J Cardiovasc Pharmacol. 1995
Nov;26(5):728-36. PubMed PMID: 8637187.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
